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ABSTRACT 
Dengue is considered as an emerging infectious disease with a wide expansion to 
more than 100 countries and territories in the world. Dengue has great social, economic 
and health impacts on endemic regions causing the disease burden to the community and 
becoming one of the most serious public health concerns. 
We described clinical and virological features of paediatric dengue cases in 
southern Vietnam in a large prospective cohort study. We used the new classification of 
WIIO 2009 to include dengue shock syndrome, severe bleeding and organ failure in the . 
category of severe dengue in data analysis. Of 7544 patients enrolled into the study with 
cO":1plete haemobiochemical results available, 2060 patients (27.3%) had laboratory-
confirmed diagnosis of dengue. The number of cases with severe dengue, dengue requiring 
parenteral fluids and uncomplicated dengue was 117 (5.7%), 156 (7.6%) and 1787 (86.7%) 
respectively. Proportions of RT-PCR positivity in the groups of severe dengue, dengue 
requiring parenteral fluids and uncomplicated dengue was 115/117 (98.3%), 149/156 
(95.5%) and 1690/1787 (94.6%) respectively. 
It is a challenge for attending physicians in the outpatient settings to recognize early 
dengue patients. A simple tool, called Early Dengue Classifier (EDC), including 
information ofage, white blood cell and platelet counts can be used alone or in combination 
with the NS 1 rapid test to make early diagnosis of dengue within 72 hours of onset illness. 
We demonstrate that the early diagnosis of dengue can be enhanced beyond the current 
standard of care using a simple evidence-based algorithm. 
A prognostic algorithm using vomiting, platelet count, aspartate aminotransferase 
and NS 1 rapid test result, called Early Severe Dengue Identifier (ESDI), can predict severe 
complications. Though the positive predictive value of the ESDI was low as seen with 
common prognostic models for a rare outcome, the results should support patient 
management and clinical trials of specific therapies. 
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Chapter 1 
INTRODUCTION 
1.1 DENGUE EPIDEMIOLOGY 
1.1.1 DENGUE EPIDEMIOLOGY IN THE WORLD 
Dengue is the most prevalent mosquito-borne viral disease in the world. Dengue 
incidence has increased 3D-fold in the recent decades with a global expansion to new 
geographic regions [I]. Nowadays, dengue is endemic in more than 100 countries where 
70 to 500 million infections are estimated to occur each year, resulting in 36 million 
clinically apparent cases and 21,000 deaths. Approximately 3.6 billion people are living in 
at-risk areas [2]. The American, South-east Asia and the Western Pacific regions are the 
most seriously affected (Figure I-I). More than 70% of these people live in the Asia-Pacific 
Region [3]. Travellers are at significant risk of acquiring the disease and also contribute to 
its spread to nonendemic regions. Population growth, urbanization and modem 
transportation contribute to the rapid increase in the number of epidemics and circulating 
viruses [4, 5]. At present, although there are several clinical trials of vaccine against deng~e, 
the only method to control or prevent the transmission of virus is to combat vector 
mosquitoes [2,6-11] The leading dengue vaccine was developed by Sanofi Pasteur and 
results from two phase III clinical trials with their tetravalent live-attenuated chimeric 
yellow-fever dengue (CYD) vaccine, have recently been reported [6, 12]. For each of the 
four dengue serotypes the pre-membrane and envelope proteins from a wild type dengue 
virus were substituted into the yellow fever 17D vaccine backbone [13]. The results from 
these trials showed that this CYD vaccine candidate provided up to 60% protection against 
dengue of any severity, and up to 80% against hospitalizations due to dengue in the first 
year of follow up after the primary vaccination series. Subsequent follow up studies have 
demonstrated the CYD-TDV vaccination was associated with an elevated risk of 
hospitalization for dengue in year 3 among children younger than 9 years of age. Therefore, 
it is necessary to have more studies on long-term vaccine efficacy for vaccines developed 
from different technologies to achieve a better result in dengue prevention [14, IS]. 
13 
Numerous vector control measures such as environmental management, larvicide 
and adulticide chemicals and human protection have had limited efficacy in stopping 
dengue transmission. The novel dengue control method using Wolbachia infected 
mosquitoes is currently being evaluated in Vietnam, Indonesia, Brazil and Columbia and 
is a promising tool for dengue control and prevention [14, 15]. Wolbachia are introduced 
into Ae. aegypti to reduce the lifespan of female mosquitoes and inhibit the replication of 
dengue virus in mosquito tissues. These properties make Wolbachia-infected Ae. aegypti 
less likely to transmit dengue. Another method called RIDL (Release of Insects with 
Dominant Lethality) has been developed by the British company Oxitec to produce fertile 
male adult mosquitoes that induce a high mortality in the descendants. The adults generated 
with this technique and released in the environment are not sterile but their descendants 
have a survival rate of 0% (this lethality can be switched off by introducing the 
antibiotic, tetracycline, into their diet). Repeated releases of sufficient numbers of sterile 
males will result in a reduction in the target mosquito population below the minimum level 
needed to support dengue transmission. 
Dengue has been designated a major international public health concern by the World 
J lealth Organization, posing great social and economic burden for the population in 
endemic regions (Figure 1-1 and 1-2). 
14 
-January lochnn 
10C 
• 
lIw ............ cI .. ......,cnd .......... _ .. .-...at_ ............. b" .......... cnd 
........ ~b,....-...f_" ..... ..,., ... ptW'C""'I_ .. _cl""'-__ 
Figure 1-1. Countrie larea at risk of dengue tJ'ansmi ion, 2008 (Taken/ram [1)) 
." 
SI 
8 
'0 
.... 
~ 
E 
:::> 
Z 
1955·1959 1960-1969 1970· 1979 1990·1989 1990-1999 2000·2007 
Year 
~ 
:f 
c 
:::> 
8 
...... 
o 
1 
E 
:::> 
Z 
Figure 1-2. Average annual number of dengue fever (DF) and dengue haemorrhagic 
fever (DHF) ca es reported to WHO, and of countries reporting dengue, 1955- 2007 
(Fakenfrom [1)) 
15 
.' 
1.1.2 DENGUE EPIDEMIOLOGY IN VIETNAM 
Vietnam is a sub-tropical country where dengue is endemic, with an estimated tens 
of thousands of cases reported every year. In 1913 a dengue-like illness was first recorded 
in north and central Vietnam [16]. In 1929 the first of many dengue fever (DF) epidemics 
took place in the south of Vietnam. However, it was not until 1963 that the first dengue 
haemorrhagic fever (DHF) outbreak in the country was officially reported in the Mekong 
Delta region of south em Vietnam [17]. From the year 1963 to 1995, there were 1,518,808 
DlIF cases and 14,133 deaths reported. Between 1975 and 2000, epidemic peaks of 
increasing magnitude occurred approximately every three to five years. The largest 
nationwide outbreak occurred in 1987 with 354,517 DHF cases and 1,566 deaths. Another 
large epidemic involved 119,429 DHF cases and 342 fatalities in 1998 [18]. Important 
features of dengue epidemiology in Vietnam from 1960 to 2010 are shown in Figure 1-3. 
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From 1996 to 2014, the annual incidence of hospitalized dengue cases per 100,000 
population in 20 southern provinces of Vietnam reached a peak at 450 in 1998, followed 
by a sudden drop in the subsequent years before gradually increasing again over the next 
decade to 263/100,000 in 2007. The same period also saw a continuous decline in the 
mortality rate from approximately 0.3% in 1996 to just below 0.1% in 2014 (Figure 1-4, 
1-5) [20]. All four dengue virus serotypes are found to co-circulate in the south Vietnam, 
but usually a single serotype dominates over multiple dengue seasons. DENV -3 was the 
predominant serotype reported in 1997-1999, followed by DENV-4 in 2000-2002. From 
2003 to 2006, the major serotype identified in hospitalized patients was DENV -2, which 
was replaced by DENV-l as the predominant type in 2007 until the present day (Figure I-
S) [20]. 
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Figur 1-4. Mo rtality rate among hospitalized dengue cases in 20 southern provinces 
of Vi tnam. (Source: Pasteur Institute HCMC, Vietnam [20)) 
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Figure 1-5. Annual incidence of hospitalized dengue cases (left-hand axis, solid bars) 
and the relative virus pr'evalence (right hand axis) between 1996 and 2014 in the 
southem 20 provinces of Vietnam. (Source: Pasteur Institute J-ICMC, Vietnam [20)) 
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Figure 1-6. Temporal trends in dengue admissions in HCMC, Vietnam, 1996 - 2009. 
Bar holV the number of inpatients with clinically diagnosed dengue each year at 
each of the major referral ho pitals in HCMC (HTD: Hospitalfor Tropical Diseases, CH1: 
Mldren 's J/ospital 1 alld CIJ2: hildren 's Hospital 2). Lines show the number of dengue 
cases ill children aged 15 years or less (triangles) and in adults over 15 years old (circles), 
combined across the tlldy sites. (Reproducedfrom [21}). 
1.2 THE DENGUE DISEASE 
. 1.2.1 THE DENGUE vmus 
engue viru e (0 NV) are divided into four antigenically distinct erotypes 
named NV-l , 0 NV-2, OEN V-3 , and 0 NV-4. These are single-stranded RNA 
iru e belonging to the family Flaviviridae, genus Flavivirus. Thi genu include also 
th We t Nile irus, Japanese encephalitis virus, tick-borne encephalitis virus and yellow 
fi v r viru . he virion comprises a spherical particle, 40- 50 nm in diameter, with a lipid 
n el p . The po ilive ingle- trand RNA genome, which is 10.7 kb in length, has a ingle 
pen reading fram that encode three structural proteins - the capsid ( ), membrane (M) 
and en I pe ( ) gl copr tein - and se en non- tructural proteins (N I, N 2A, N 28, 
N 3, N 4A, N 48 and N 5) (Figure 1-7). Among non-structural proteins, envelope 
gl pr lein, N I, i of diagno tic and pathological importance. Dengue viruses have two 
c nerved -linked glyco ylalion ites at A n-67 and Asn-IS3. The glycosylation site at 
A n-153 i con er ed in mo t fl av iviru e , while the glycosylation site at Asn-67 appears 
I be unique t dengue iru e and i absent in other class 2 enveloped viruses. The loop 
bearing the glycan on A n-IS3 is two re idues horter in OENV-3 than in the other dengue 
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vtru erotypes. Both glycan ha e been implicated in cellular attachment and viral entry 
[22-24]. The glycosylation pattern differ according to DENY serotype and even among 
different trains, a .. ell a the cell in which the viru i propagated. The degree and 
po ition ofN-linked glycans afFect the antigenic propertie of DENY [23,25,26]. Unlike 
20 to 30 ears ago \ hen serotype 3 and 4 were not found in America and Africa al l four 
serotype are now circulating in h perendemic region including Asia Africa and America 
[27]. 
5'UTR 
NSS 
3' UTR 
Figur 1-7. he dengue irus genome. (Reproducedfrom [27]) 
1.2.2 THE VE TOR OF DEN UE 
Thc highly domc ticatcd, an thropophi lic Aedes aegypli mo quito is the primary 
ector F dengue viruse . The dengue iru is tran mitted to human through the bite of 
inft cted Ae. aegypli mo quitoe . he mo quito become inFected with dengue viru when 
it bite a p I' on who ha dcngue iru in their blood (Figure 1-8) [28]. 
Thi mosquito inhabit tropical and ubtropical area and i widely spread around 
the world mo tly between latitude 35°N and 35° . Iligh ea ona l rainfall and hi gh 
en ironmental temp rature, the latter more important than the former are the two main 
Factor contributing to e, pan ion of the Aede aegypli mo quito population and habitat 
con equently resulting in increased dengue tran mis ion. Because of low temperature on 
highland or mountain , Aede' aegypli is rarely found above 1,000 metres. When the 
temperature increase, all stage oFthe Aede' life cycle become horter - leading to a larger 
mo quito population, increa ed Feeding rate and shorter extrin ic incubation periods, i.e. 
reducing the time that dengue iru e dis eminate to alivary glands in infected adult 
mo quitoe . 
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Male and female adult mosquitoes feed on nectar of plants; however, female 
mosquitoe need blood in order to produce eggs, and are active in the daytime. Eggs have 
the abi lity to survive drying for long periods of time, allowing them to be easily spread to 
ne\ locations. Artificial or natural water containers such as flower pots, discarded tires, 
plate under potted plant ,cemetery vases, buckets, tin cans, clogged rain gutters, etc. that 
are \ ithin or close to places where humans live are idea l larval habitats for Aedes aegypli 
mo quito. 
Other mo quito species in the genus Aedes - including Aedes albopietus and Aedes 
po/ynesiensis, and Aedes seutel/aris - have a limited ability to serve as dengue vectors. 
hese Aedes specie have particular ecology, behaviours and geographical distribution, 
, hich are thought also to have influenced the expansion of disease although to a lesser 
extent than Aedes aegypti [I]. 
Figur 1-8. Dengue transmi sion [28] 
The dengue virus i :preCld through Cl hUlllan-lo-mosquito-to-human eycle oJ Iran mission. 
1.2.3 LTNICAL MANIFESTATIONS 
he majority of 0 NV infections are asymptomatic. Symptomatic DENY infection 
ha a broad clinical spectrum, ranging from a non-severe acute febrile illness sometimes 
.. ith e idence f mild a cular leakage and haemostatic derangements, to a severe 
~ rm r illne \ ith h povolemic shock due to plasma leakage, severe bleeding 
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and/or severe organ dysfunction [1,29]. After an average incubation period of 4- \ 0 days 
(range 3 - 14 days), the illness begins abruptly and is followed by the three phase - febrile, 
cr itica l and recovery (Figure 1-9). 
Day. cl ill ... " 
PoI,eliai diniocl illoo, 
Serology ond ';roIogy 
Courle cl dengue il lno .. : 
2 3 4 5 6 7 8 9 10 
Dehydration 
Organ impairment 
Reabwplion 
"uid ...... ~ood 
Holl'aI:;';. ( ...... ...  : ~I'I 
~~ ___ -l 
Viraemia 
F.brilo Criliocl R,"""'ry phole. 
Figure 1-9. The COur e of den gue iIIne s 
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Figure 1-10. uggested dengue case classification and levels of severity. (Taken from 
WHO lIideline, 2009) 
1.2.3.1 Febrile pha e 
Patient typically dcvclop a sudden rise in temperature, usually lasting 2 - 7 days, 
and i frequ ntly a ociated with a flushed face, skin erythema, genera lized body ache 
myalgia, arthralgia and headache [30]. A faint macular or maculopapular rash is present 
in ome ca e , but i evanescent and easily miss. Some other manifestations include Sore 
throat, injected pharynx and conjunctival injection. It is often for the patients to have 
an rexia, nau ea and vomiting. These often non-specific signs and symptoms, particularly 
in the fir t few day of fever, can make it difficult to clinically distinguish dengue from 
n n-dengue illne se uch a influenza, measles, infectious mononucleosis, scarlet fever, 
mcningiti , acute appendicitis [I]. In add ition, clinical experience suggests that early 
clini al ign and ymptom are indistinguishable between patients with severe and 
line I11plicatcd disease evolution [27, 31 , 32]. A positive tourniquet test in this phase 
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increases the probability of dengue. This test has been considered as supportive evidence 
for a clinical diagnosis of dengue, but since spontaneous petechiae are often present 
anyway and the test can be positive in other infections, the sensitivity, specificity and 
diagnostic utility are limited [32,33]. Mild haemorrhagic manifestations like petechiae and 
mucosal membrane bleeding (e.g. nose and gums) may be seen. Massive uterine bleeding 
(in pubertal females and women of childbearing age) and gastrointestinal bleeding may 
occur during this phase but is not common [32, 34]. The liver is often enlarged and tender 
after a few days of fever. Laboratory investigations show a progressive decrease in 
leucocyte and platelet counts in this period, sometimes with mild increases in hepatic 
transaminases [I, 32]. 
1.2.3.2 Critical phase 
Most patients begin to recover when the fever subsides but in a small number of 
cases, estimated to be less than 5%, the patient deteriorates around the period of 
defervescence, which is. usually between days 3-7 of illness. This critical stage coincides 
with the leakage of plasma when there is the increase in the permeability of the capillary 
system [35]. Clinical signs of plasma leakage include ascites, pleural effusions and 
haemoconcentration. Severe plasma leakage can cause cardiovascular collapse, the so-
called dengue shock syndrome (DSS), which is usually imminently preceded by warning 
signs such as abdominal pain, persistent vomiting and hepatomegaly. On clinical 
examination, DSS presents with cold or clammy skin, restlessness, rapid and weak pulse, 
narrow pulse pressure or hypotension [1]. Haemorrhagic manifestations are seen more 
frequently in this period since thrombocytopenia and coagulopathy may become more 
prominent. However, most of the bleeding features are mild either on the skin or superficial 
mucosa such as petechiae, easy bruising, epistaxis and gingival bleeding. In some 
circumstances, severe haemorrhage like gastrointestinal bleeding and large hematoma at 
venipuncture sites may occur especially for patients with prolonged shock. Of special 
importance is that severe bleeding can occur in adults even without significant plasma 
leakage [36, 37]. Inappropriate management of DSS can result in prolonged shock, 
metabolic acidosis, coagulopathy, liver impairment, multiple organ failure and death. The 
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critical phase with clinically significant plasma leakage usually lasts 24-48 hours then 
patients enter the recovery phase. 
1.2.3.3 Recovery phase 
Surviving patients recover within 2-3 days with the normalization of vascular 
permeability and re-absorption of extravascular compartment fluid. Patients feel better, 
resume appetite with stable hemodynamic status and diuresis. A second skin rash often 
appears during the transition from critical to recovery phases. This so-called recovery rash 
ranges from a mild maculopapular rash to a very florid appearance with intense erythema 
and dense petechiae interspersed with islands of pale skin. Sinus bradycardia or arrhythmia 
can sometimes occur in this stage but does not affect the general well-being. The 
haematocrit returns to normal though it may temporarily decrease below the baseline 
values due to the dilutional effect of the re-absorbed fluid. The white blood cell and platelet 
count increase soon after defervescence with a faster recovery of white blood cell count 
compared to that of the platelet count. 
In addition to severe ascites and/or pleural effusions, especially in case with a large 
amount of intravenous fluid given during the critical phase, overload of re-absorbed' fluid 
can cause respiratory distress [1]. A rare complication in the convalescent period is 
pulmonary oedema or congestive heart failure due to excessive fluid therapy. 
1.3 DENGUE CASE CLASSIFICATION 
The traditional World Health Organization (WHO) dengue classification and 
management scheme in 1997 divided symptomatic dengue into three groups: 
undifferentiated fever, dengue fever and dengue haemorrhagic fever. Dengue 
haemorrhagic fever was again classified into four grades of severity, where grades III and 
IV were defined as dengue shock syndrome [38]. In clinical practice, this classification 
system has shown many drawbacks because of the changes in dengue epidemiology with 
the expansion to many new geographical regions and older age groups. Also, the old 
classification might make clinicians incorrectly define severe dengue as dengue fever 
especially in adults and did not pay attention to organ failure in the case definition [39-4 I]. 
As a result, a revised WHO dengue case classification was issued in 2009 after an extensive 
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prospective study was conducted across many Southeast Asian and Latin American 
countries, dividing dengue into dengue without warning signs, dengue with warning signs 
and severe dengue [1, 42]. Severe dengue presents one or more of the following 
complications: (a) plasma leakage that may lead to shock and/or fluid accumulation with 
respiratory distress, (b) severe bleeding, and/or (c) severe organ impairment (hepatic 
dysfunction, renal failure, encephalopathy or encephalitis, cardiomyopathy and other 
organs) (Figure 1-10). 
1.4 CLINICAL MANAGEMENT 
There has been no specific antiviral medicine or any vaccine available for the 
treatment of dengue to date. Appropriate management for patients with dengue is 
supportive treatment by antipyretics and oral fluid intake to prevent dehydration due to 
plasma leakage [1,43]. Aspirin and other nonsteroidal anti-inflammatory drugs including 
( ibuprofen should be avoided due to the possibility of worsening bleeding complications 
[44]. It is possible to manage most patients at home if there are no warning signs. Patients 
are required to come back for re-examination and takcn blood to check the haematocrit and 
platelet count on a daily basis if a clinically suspected dengue is diagnosed [45,46]. If the 
disease progresses unfavourably with the presence of warning signs or a rapid increase in 
haemoconcentration and/or severe decrease in platelet count, patients must be hospitalized 
for close observation. Volume replacement by intravenous therapy with isotonic crystalloid 
solutions is indicated for those patients with persistent vomiting, rapidly continuous 
elevation of the haematocrit or any signs of cardiovascular compromise [47-49]. Adjust the 
volume and rate offluid infused to maintain the hemodynamic status, especially the tissue 
perfusion and diuresis (at least 0.5ml/kglhour) [I, 50]. In case of shock, resuscitation with 
the intravenous fluid therapy is much more aggressive under careful monitoring the vital 
signs, time of capillary filling, haematocrit and diuresis. ]fthe patient's state does not show 
improvement, it is then necessary to switch to using colloids and measuring the central 
venous pressure as a guide for fluid replacement [I, 49, 51]. The time for fluid infusion 
usually lasts 24-48 hours corresponding to the critical phase. Patients with respiratory 
distress can be managed by oxygen support via nasal cannula or continuous positive airway 
pressure [52]. Fresh whole blood or packed red cells can be given to patients with severe 
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bleeding, which sometimes manifests discreetly only by the state of shock while the 
haematocrit decreases [50, 53, 54]. 
1.5110ST COMPONENTS AFFECTING DENGUE DISEASE 
MANIFESTATION AND PROGRESSION 
Many factors influence the susceptibility of the human to and/or the severity of 
disease including age, sex, immune status, genetic predisposition, nutritional status and co~ 
morbidities. 
1.5.1 Immune status 
Infection with one serotype of DENV provides lifelong immunity to that serotype, 
but results only in partial and transient protection against subsequent infection by the other 
three serotypes. Importantly, many studies have shown that secondary infection with a 
different DENV type is a major risk factor for DHFIDSS, possibly due to antibody~ 
dependent enhancement [55-58]. In ihis mechanism, non-neutralising antibodies increase 
the infected cell mass and virus production. The large infected cell mass and the high viral 
load are a prelude for severe disease development. The binding of residual heterotypic 
nonncutralizing antibodies from the earlier infcction with the new virus is hypothesized to 
facilitate viral entry and replication. The resulting increased viral load triggers an immune 
cascade that alters microvascular function and causes a transient increase in vascular 
permeability that may be severe enough to cause DSS. DENV-specific antibodies also exist 
in newborn infants; when these passively transferred maternal antibody levels wane, the 
increase in DlIF occurring during the first infection is held as evidence for the importance 
of ADE in the pathogencsis of severe dengue [59-62]. 
1.5.2 Age 
A majority of cases occur in children, especially in the school age range. However, 
dengue can occur at all ages. Infants under one year may experience symptomatic disease 
with high risk of severe dengue and death [21, 63]. Overall, mortality rate was highest in 
young children with DSS and decreased with increasing age [21]. During recent years, the 
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incidence of dengue in adults has increased rapidly, often accompanied with underlying 
chronic disorders that can cause significant morbidity and mortality [64, 65]. A plausible 
explanation for this trend could be a reduction in the force of infection due to 
socioeconomic development and/or improved vector control such that fewer people are 
exposed during childhood leaving a larger reservoir of susceptible adults [66]. A second 
explanation could be the movement of adults into endemic regions where there is a risk of 
exposure to infected mosquitoes. Alternatively the flow of susceptible individuals into the 
population decreases due to lower birth and death rates in transitioning economies, which 
increase the lifespan of immune individuals and the likelihood that an infectious mosquito 
will feed on an immune individual [67]. 
1.5.3 Sex 
A higher proportion of dengue cases are reported to occur ill male than female 
{ patients [21,68]. However, it has been shown that the risk for DSS and death from this 
complication is higher in females [21, 68]. The hypothesis for this is either a more robust 
cellular immune response or a higher intrinsic susceptibility to capillary permeability ill 
females than males [16] . 
1.5.4 Race 
Race has been identified as an individual risk factor since DlIFIDSS is more 
prevalent in white compared to black persons. Dengue outbreaks in Cuba have provided 
evidence of a reduced risk of people of African descent for DlIF/DSS compared to those 
of Caucasoid race. These observations from Cuban dengue outbreaks have significant 
epidemiological interest, as the differences ill susceptibility to DIIF/DSS among 
racial groups in Cuba coincide with that reported in African and Black Caribbean 
populations [69, 70]. Serologic studies showed that a high proportion of Africans and 
those who are genetically of African origin in I laiti had the presence of antibody to dengue 
virus, but the number of symptomatic dengue cases reported among these groups was smaIl 
[71, 72]. One of the plausible explanations is that there could be the presence of a 
disease "resistance" gene in black persons. 
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I.S.S Host genetics 
Several host genetic factors such as some human leukocyte antigen (HLA) class I 
allclcs. a promoter variant ofCD209 (DCSIGNI-336). some tumour necrosis factor-a and 
Iymphotoxin-a polymorphism genes and AB blood group have been identified as risk 
factors for severe dengue [5, 73-77].1 lowever. most of the studies to date have been small 
and the results have not been replicated in second populations so the significance 
remains uncertain. Recently however a large genome-wide association study from Vietnam 
has identified susceptibility loci for DSS at MICa and PLCEt, and this has since been 
validated in Thai children [78, 79]. 
I.S.6 Nutritional status 
It has been shown that malnourished children had a lower risk of contracting dengue 
infection while obese children had a greater risk of infection with dengue viruses [73-75]. 
Although some studies about nutritional status and dengue severity have reported 
inconclusive results, most studies conclude that obesity is a risk factor for developing 
DIIF/DSS and children with malnutrition had a reduced risk of severe disease [73, 76]. A 
plausible explanation forthis is based on the host immune response. Malnourished children 
are spared from severe DIIF/DSS because they have a suppressed cellular immune 
response. On the contrary, obese children are expected to have a stronger immune response 
than nonnal children. so they are at higher risk of developing severe dengue [16. 76, 80]. 
Complications of fluid overload were found more in obese patients compared to normal 
and malnourished patients [75]. In obese children, it is more difficult to estimate fluid 
replacement and intravenous fluid based on body weight may be too much resulting a 
higher complication rate for overhydration among these patients. In contrast. Kalayanarooj 
reported in a review of 4,532 cases with dengue infection that malnourished children had 
a higher risk of developing shock than nOnllal and obese patients [75]. Other studies 
suggested that the nutritional status does not influence the course of dengue infection, i.e. 
excess nutrition does not appear to be a risk factor for severe dengue. nor does malnutrition 
appear to be predictive of good outcomes [74, 81-83]. 
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1.5.7 Co-morbidities 
It has been reported that patients with certain co-morbidities like diabetes mellitus, 
hypertension, chronic renal failure, asthma, and allergies are at high risk of developing' 
DHFIDSS [5, 77]. However, there is little knowledge about this field. Changes of the 
vascular endothelium occurring in diabetes mellitus and allergies might trigger biological 
changes resulting in increased capillary fragility and vessel permeability observed in DHF 
patients. Patients with history of allergies often have constantly activated immune system 
and there is liberation of pro inflammatory cytokines in tissues, particularly in endothelium 
[83]. Similarly, in type-2 diabetes mellitus, the activation ofT-lymphocytes and release of 
cytokines like gamma interferon and tumour necrosis factor alpha ultimately increase the 
capillary fragility and permeability [84]. Similar physiopathological mechanism has been 
observed in development of Dl {F/DSS. 
1.6 DIAGNOSIS OF DENGUE 
1.6.1 DIFFERENTIAL DIAGNOSIS OF DENGUE 
Dengue and severe dengue can be misdiagnosed with other diseases, especially 
during the early febrile phase because of non-specific signs or symptoms [I]. It is extremely 
important to know the regional epidemiology offebrile diseases and the different stages of 
dengue infection to make the differential diagnosis. Many severe infectious diseases such 
as malaria, leptospirosis and typhoid fever are sometimes very similar to dengue. During 
the febrile phase, dengue must be differentiated from flu-like syndromes (influenza, 
measles, chikungunya, etc.), or various conditions with rashes and fever (rubella, measles, 
chikungunya, erythema infectiosum, infectious mononucleosis, etc.). Severe dengue with 
dengue shock syndrome or neurologic manifestations can mimic sepsis, meningococcal 
infection, or other aetiologies of encephalitis. Abdominal pain in dengue with warning 
signs is sometimes very severe and challenging for the differential diagnosis of an acute 
surgical abdomen. 
1.6.2 LABORATORY DIAGNOSIS OF DENGUE 
1.6.2.1 Virus isolation 
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DENY me found in serum/plasma and tissues for approximately 2 to 7 days, 
corresponding to the febrile phase. Though virus isolation by cell culture and from 
mosquitoes is the gold standard, it has gradually been replaced by the RT-PCR method for 
the detection of DENY during the febrile period (see below). Dengue serotypes can be 
identified by immunofluorescence assay using serotype-specific monoclonal antibodies. 
Yirus isolation is not suitable for routine clinical management because the technique is 
complicated and takes 1-2 weeks to give the results [1]. 
1.6.2.2 Viral nucleic acid detection 
The reverse transcriptase polymerase chain reaction (RT-PCR) methods have been 
used to identify dengue RNA in plasma or tissue since the early 1990s [85-87]. To date, 
various RT-PCR techniques have been developed for the diagnosis of dengue infection and 
serotyping based on the different amplicon sizes. More recently, real-time RT-PCR has 
become a quantitative method to determine the RNA viral load early in the viraemic stage, 
which is considered a prognostic factor of disease severity. Real-time RT-PCR can be 
either "singleplex". detecting on~ single serotype in a separate reaction, or "multiplex". 
identifying all four serotypes in the same reaction [88-90]. However, RT-PCR is not 
available at every health facilities because it requires expensive equipment and specialized 
training. 
1.6.2.3 Viral antigen detection 
NS I is a virus protein secreted from infected cells into plasma within the first 1-3 
days of fever and may persist in the peripheral blood circulation for up to 9 days from 
illness onset [91-93]. The availability of commercial antigen-capture assays, including 
ELlSA and rapid test, that detect the DENV NS I represents a major advance in early 
dingnosis. It has been shown that the speciticity of these kits is very high, up to 
approximntcly 100%, while the sensitivity varies depending on the manufacturer. The 
sensitivity of NS 1 assays depends on the day of illness, and is higher within the first three 
days of fever. Primary infection has also been documented to have higher sensitivity than 
secondary infection [94-98]. The hallmark ofNS 1 antigen detection is that this method is 
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simple and can give the results quickly. However, this method generally cannot 
differentiate between the different virus serotypes. 
1.6.2.4 IgM antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) 
MAC-ELlSA is an inexpensive and simple test with a high sensitivity and relative 
specificity to detect DENV-reactive IgM in serum or plasma on day 5 or more after the 
onset of fever. It can be cross-reactive with other flaviviruses including Japanese 
encephalitis, St. Louis encephalitis and yellow fever probably due to the use of whole cell 
virus antigen [99]. However, this limitation can be reduced by using an in-house MAC 
ELlSA with reagents derived from co-circulating flaviviruses as controls. [100]. There are 
also rare reports offalse positive results where sera were taken from patients with malaria, 
leptospirosis and past dengue infection [101]. 
1.6.2.5 IgG antibody-capture enzyme-linked immunosorbent assay (GAC-ELISA) 
GAC-ELlSA follows the same procedures as MAC-ELlSA and also has a broad 
cross-reactivity among flaviviruses [102, 103]. A fourfold or greater increase in IgG 
antibodies in acute and convalescent paired sera is defined as recent infections. As a 
consequence, IgG assays are useful for sero-epidemiological surveillance. GAC-ELlSA 
can differentiate primary and secondary infections by comparing the IgM/lgG ratio [lot, 
104, 105]. 
1.7 EARLY DIAGNOSIS OF DENGUE AND PROGNOSIS OF SEVERE 
DENGUE - OBJECTIVES OF TillS THESIS 
In Vietnam and many other endemic countries it is not possible to hospitalise every 
patient with cl inically suspected dengue for observation and therefore triage is an important 
and necessary step [106]. An early laboratory diagnosis of dengue can assist in patient 
triage and management by directing clinical attention to the appearance of capillary 
permeability, for which supportive oral and/or parenteral fluid therapy is recommended to 
prevent circulatory compromise. Furthermore, an accurate dengue diagnosis helps to 
exclude other severe diagnoses, e.g. sepsis, and prevents unnecessary antibiotic usage [1]. 
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A prompt diagnosis of index cases can also facilitate early vector control activities in the 
community so as to mitigate further transmission. Finally, given our understanding of the 
dynamics of viraemia, host response and clinical complications in dengue, it is likely that 
the success of novel interventions with anti-viral drugs or corticosteroids to modulate the 
host-prointlammatory response will be dependent on early ($3 days) clinical, or better, 
laboratory diagnosis. 
The detection of NS I antigen of dengue virus by rapid assay will help make early 
diagnosis of dengue and assist clinicians in patient triage and care-management. As an 
example. the sensitivity and specificity of NS 1 detection by ELISA and rapid diagnostic 
test (ROT) in Vietnamese children with dengue were recently prospectively defined [96]. 
In the first 3 days of illness, sensitivity and specificity were -80% and 100% respectively 
in laboratory-confirmed dengue cases, suggesting a place for such a test in early diagnostic 
eff0l1s [96, 98, 107. 108]. Furthermore, there are several lines of evidence to suggest that 
the sensitivity of early NS 1 detection will be highest in children who subsequently develop 
severe dengue. In hospital-based studies, early NS 1 concentrations [1091, and viraemia 
levels [110, 111], were higher in th~ first 72hrs of fever in Thai children who developed 
severe dengue. Ilowevcr, the sensitivity of the NS 1 detection assay is lower in patients 
with secondary infections and therefore, despite the higher NS 1 levels there may be 
antibody antigen complexes that make the test less sensitive. Furthermore, clinical 
experience suggests that early clinical signs and symptoms are indistinguishable between 
patients with severe and uncomplicated disease evolutions. 
The aims of this thesis are as follows: 
1) Describe the clinical and virological characteristics of paediatric dengue 
infection. 
2) Develop a simple diagnostic algorithm incorporating simple clinical history, 
examination findings and laboratory features to serve as a useful tool for making early 
diagnosis of dengue in the outpatient setting and compare the performance of this 
diagnostic tool with that of NS 1 rapid test. 
3) Develop a prognostic algorithm for the early identification of severe dengue in 
children. 
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By addressing these aims, physicians at the outpatient setting or primary healthcare 
level can get benefit of overcoming their problems related to overlooking dengue patients 
especially those who are at high risk of progression to severe complications. In order to 
fulfil these objectives, prospective studies with large sample sizes, early recruitment and 
well-characterized patients with different degrees of severity are important to understand 
better the disease pathology and to uncover early markers of dengue severity. Last but not 
least, by identifying cohort at risk of severe dengue, it will have implications for the 
targeting of future vaccination strategies and clinical trials of therapeutic interventions. 
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Chapter 2 
MATERIALS AND METHODS 
This chapter describes the general procedures including study design, patient 
enrolment and analysis plan used in my PhD project. A detailed presentation of the 
statistical methods will be included in the relevant chapters. 
2.1 Human Research Ethics 
The study protocol was approved by the Ilospital for Tropical Diseases scientific 
and ethical committee and the Oxford University Tropical Research Ethical Committee 
(OXTREC 35-10). The accompanying parent/guardian of each child provided written 
informed consent. 
2.2 Study design 
A cohort study of dengue in children presenting to the outpatients department of 
collaborating hospitals in Vietnam including Hospital for Tropical Diseases (IlTD), 
Children's Hospital I (CIII), Children's Hospital 2 (CII2), Tien Giang Provincial Hospital 
(TGH), Dong Nai Children's Ilospital (DNII), Binh Duong Provincialllospital (BOIl) and 
Long An Provincialllospital (LAII). 
2.3 Patient enrolment 
Recruitment occurred in the public sector outpatient departments of collaborating 
hospitals. These outpatient departments function as primary care providers to their local 
communities. A patient presenting to one of the study sites was eligible for enrolment if 
they met the following inclusion criteria - a) fever at presentation (or history offever) and 
less than 72 hours of sym pto m history, b) in the opinion of the attending physicians dengue 
was the most likely diagnosis, c) 1-15 years of age inclusive, d) accompanying family 
member or guardian had a mobile phone and e) written infonned consent for the child to 
participate was provided by the parent/guardian. Patients were excluded if - a) the 
I attending physician believed they were unlikely to be able to attend follow-up or b) the 
attending physician believed another (non-dengue) diagnosis was more likely (Figure 2-1). 
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Patient ellr Iment oc urr d consecutively during normal clinical hours on weekdays 
wi thout restri ti n. All patient \ ere enro lled into the study before the attending physician 
re i ed the r ult of any r utine laboratory tests. 
Daily follow-up 
• phone call to family 
• ascertain outpatient/inpatient status 
• detection of hospitalised cases and clinical endpoints of interest 
• ~6 days after fever onset collect a convalescent blood sample from 
10% of study participants and 100% of hospitalised cases 
Inclusion criteria 
• 1-15yrsofage 
• Fever and clinical 
signs/symptoms suggesting 
the most likely diagnosis of 
dengue 
• 72 hrs or less of fever 
• Accompanying family 
member/guardian has mobile 
phone 
• Written informed consent 
Exclusion criteria 
• patient who is unlikely to be 
able to attend follow-up 
• patient in whom another 
diagnosis is more likely 
Fever day 
Enrolment and data collection 
History 
Signs/symptoms 
Demographic 
• age 
• sex 
• height and weight 
Clinical management 
• ambulatory/inpatient 
Laboratory 
NS1 tests 
• CBC 
• AST/AL T and CK 
• Sample stored for 
diagnostic 
serology and RT-
PCR 
l1'iglll' 2-1. ullImIH'yof crccning, cnrolillcnt, inves tigations and follow-up 
2.4 I)cmogmphic, clinical and laboratory data collection 
t the till1 r enr 101 nt, information on the patient's age, sex, illnes history, 
pr . cllting ign nnd ymp! m \ er recorded in a case report fonn. The definitions used 
upp rt tandardized data apture are ho\ n in Table 2- 1. Blood samples were drawn 
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for routine haematology, biochemistry including albumin, aspartate aminotransferase, 
creatine kinase and NS I rapid test. All NS I rapid tests (NS I Ag STRIP, BioRad) were 
performed on the same day of patient enrolment by one of two trained laboratory 
technicians at the Hospital for Tropical Diseases. Routine haematology results, but not 
biochemistry or NS I rapid test results, were made available to the attending physician, who 
decided on the management approach, i.e. hospitalization or ambulatory follow-up. 
2.5 Patient follow-up 
A 2nd blood sample for the purposes of serology was collected around the time of 
defervescence from all patients that were hospitalized anytime during their acute illness. If 
the patient was managed solely on an ambulatory basis for the duration of their illness, then 
a 2nd early convalescence blood sample for the purposes of serology was collected only 
from a randomly selected 10% ofthis patient population. The randomization code to select 
ambulatory cases for follow-up was generated by a clinical data management system called 
"CLlRES", a software developed by the Department of Infomlation at the Oxford 
University Clinical Research Unit. The rationale for collecting a convalescent blood 
sample from 10% of participants and 100% of hospitalized patients is explained in Section 
2.6 below. This ICH-GCP compliant, clinical data management system also stores all 
clinical and laboratory data. Demographic and clinical data were double entered. Electronic 
data files containing haematological results were uploaded directly to CLlRES. 
Independent study monitoring was performed by the Clinical Trials Unit of the Oxford 
University Clinical Research Unit which examined adherence to the trial procedures, data 
collection and recording and compliance with ICII-GCP. 
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Table 2-1. Clinical and demographic features recorded at the time of study enrolment 
Variable Definition 
-
1. Day of illness (days) 
1. Age (years) 
2. Sex 
3. BMI (kg/(mf) 
Day of illness at enrolment 
Age in years 
Male/Female 
Body mass index (BMI) = weight (kg) !height (m) A2 
-
4. Temperature at enrolmcnt rq Axillary temperature at enrolment 
S. Vomiting (YeslNo) Any episode of vomiting in history of illness 
6. Skill blecding (YeslNo) Ilistory or clinical examination shows that the patient has 
skin bleeding, e.g. petechiae or ecchymosis. 
7. Mucosal bleeding (Ye sIN 0) Any frank bleeding from any mucosal site e.g. epistaxis, 
gingival bleeding, gastrointestinal bleeding, or urogenital 
bleeding in history of illness or medical examination 
8. Abdominal pain (YesINo) 
9. Rash (YeslNo) 
10. Flush (YeslNo) 
11. Conjunctival injection 
(YesINo) 
12. WBe (lOJ/mm3) 
13.IICT (%) 
14. Platelet COllnt (t 03/1111n3) 
t 5. AL13 (glL) 
16. AST (UlI) 
17. CK (l1Il) 
Ilistory or clinical examination shows that the patient has a 
painful feeling at the abdomen by self-reporting or elicited 
on gentle palpation. 
Bright red-purple non-petechial dots appearing on the 
arms, legs, and possibly pink-red patches all over the body. 
Marked redness in the face and often other areas of the 
skin caused by dilatation and congestion of the capillaries 
that blanches with pressure. 
Redness (bright red or pink) of the conjunctiva fading 
towards the limbus due to dilatation of the superficial 
conjunctival blood vessels. 
Absolute white blood cell count at enrolment 
Ilacmatocrit at enrolment 
Platelet count at enrolment 
Dlood albumin concentrations 
Dlood aspartate aminotransferase concentrations (Iog2-
transfomled) 
Dlood creatine kinase concentrations (Iog2-transformed) 
..... ------------------------------------------------------------------
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2.6 Dengue diagnostics and case definitions 
The gold standard diagnostic result was a composite derived from three tests; RT-PCR, 
JgM serology and NS I detection by EUSA. First, all enrolment plasma samples were tested with 
a validated, quantitative RT-PCR assay to detect DENV RNA [112]. Next, any enrolment plasma 
samples that were negative in the RT-PCR assay were tested using the Platelia Dengue NS I Ag 
ELlSA assay (BioRad) and scored according to the manufacturer's instructions. Samples with 
equivocal results were repeated and if still equivocal they were scored as negative. Next, JgM 
EUSA serology (Panbio, Brisbane, Australia) was performed according to the manufacturer's 
instructions for patients who had paired plasma samples (enrolment and early convalescence) 
and who were negative in both the DENV RT-PCR assay and Platelia Dengue NS I EUSA. 
Any patient who was - a) DENV RT-PCR positive, b) NSI EUSA positive, or c) had DENV 
IgM seroconversion in paired plasma samples, was classified as a laboratory-confimled 
dengue case. IgM seroconversion was defined as a change in the MAC EUSA test result from 
negative to positive in paired plasma samples with the 2nd sample collected 6 or more days after 
illness onset and >2 days after the 151 sample. A positive dengue IgO of either the acute or 
convalescent blood sample at discharge was defined as "probable secondary infection"; otherwise 
that both the two samples were negative for dengue IgO was considered as "probable primary 
infection". 
Any patient who was DENV RT-PCR negative, NSl EUSA negative and did not JgM 
seroconvert in paired plasma samples was classified as "not denguc". Any paticnt who was DENV 
RT-PCR negative and NS 1 EUSA negative at the time of enrolment, but did not have paired 
samples available for serology, was classified as a "presumptive not-dengue" case. For analysis, 
data from "not dengue" and "presumptive not-dengue" cases were pooled. 
The identification of "not dengue" cases allows the diagnostic spccificity of the NS 1 
tests to be assessed. I did not however attempt to collect convalescent blood samples from 
all patients. Instead, the patients from whom I collected a 2nd sample would be determined 
by a randomization codc and represented 10% of the overall population. In addition, I collected 
a convalescent blood sample from all hospitalized patients, irrespective of clinical diagnosis, at the 
time of discharge from hospital. The principal reason for not making the difficult effort 
to collect a convalescent blood sample from all study participants, and thereby identifying all of 
the "not dengue" cases, is that I do not believe it is necessary to have such a large popUlation of 
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"not dengue" cases in which to measure specificity and negative predictive value (NPV), 
particularly when there is substantial existing literature, including from Vietnam, that describes 
the excellent specificity of these NS I antigen detection assays [96, 113-118]. Instead, the 
pragmatic focus of this study is on measuring the sensitivity of the tests for an early laboratory 
diagnosis of cases that will develop severe complications and use this as a platform for developing 
a prognostic algorithm. 
2.7 Laboratory methods 
Qlltllil(llb'e NS I EL/SA 
Dio-Rad Dengue NS 1 AS Platelia ELISA was carried out according to the manufacturer's 
instructions. Dricfly, 50JlI of plasma or control sera (including one calibrator, one negative and 
one positive control sera) were incubated directly and simultaneously with 50JlI of diluent and 
100~ll of diluted conjugate at 370 C in microplate wells for 90 minutes. After washing, 160JlI of 
chromogen solution was added into each well and incubated for 30 minutes in the dark at room 
temperature. The enzymatic reaction was stopped by adding 100JlI of IN sulphuric acid solution. 
The optical density (OD) was read at 450/620 nm. The presence of NS 1 antigen in each sample 
was detennincd by comparing the OD of the sample to the OD of the calibrator (Sample Ratio). 
The test would be valid if aI mean of calibrator OD was greater than 0.2, bl the negative control 
was lower than 0.4 times the calibrator OD and cl the positive control was greater than 1.5 times 
the calibrator OD. Result interpretation was as follows: 
}.- If Sample Ratio <0.5, result was interpreted as negative 
}.- If Sample Ratio> 1.0, result was interpreted as positive 
)i;. If 0.5 :5 Sample Ratio:5 1.0, result was interpreted as equivocal 
Antl- DENV IgM/lgG capture ELlSA assay, 
Drietly, 96- well plates (Maxisorp, Nunc) were coated with) OOJlllwell of anti-human fgM 
(A042S, Oako) or anti-human IgO (12136, Sigma) at a dilution of 1 :2000 in 0.05 M carbonate-
bicarbonate buffer, p119.6 (C3041, Sigma) overnight at 4oC. After plates were washed 3 times with 
phosphate buffer saline-TWEEN (PDST), each well was blocked with 200JlI of3% bovine serum 
albumin (BSA, A 7906, Sigma) in phosphate buffer saline (PDS) for 2 hours at room temperature. 
The plate was subsequently washed again and then incubated for 2 hours at room temperature with 
41 
I OO~I per well of positive, negative controls or samples which were diluted I: I 00 in 0.1 % BSA-
. . 
PBS. After washing, the test was continued by adding I 00~1 of pooled C6/36 cultures of OENVI-
4 antigen to each well and incubating at 40 C overnight. Next, the plate was washed again and 
incubated with a cocktail of mouse monoclonal anti-OENV 1-4 E protein antibodies (l OO~I/well) 
for I hour at room temperature. The antigen-antibody complex was detected with 100111 of 1:2000 
diluted anti-mouse Ig Horseradish Peroxidase (HRP) (P260, Oako). After the final washing, 
substrate o-phenylenediamine dihydrochloride (OPO, Sigma) was added the incubated for 30 
minutes and the colour metric reaction was stopped by adding 50111 of 10% H2S04. The optical 
density (OD) was read at 490nm with Microplate Reader and analysed with Microplate Manager 
software (Biorad). 
Positive control was a mixture of plasma samples from Vietnamese acute dengue patients who 
, 
had strong positive results with the IgM capture ELlSA assay. Negative control was a mixture of 
plasma from dengue-na'ive healthy adult volunteers who had just arrived from regions without 
known dengue transmission and who had negative results on the Panbio IgO indirect ELlSA. 
The cut-off value (CO) for positivity was defined as being 5 times higher than the average 
OD of negative contr:ol samples (OOn) after the subtraction of background OD (OOb). The sample 
ratio (Rs) was calculated by subtracting background OD from the test sample OD (OOs) then 
dividing by the assay cut-off. In summary, the formulas were calculated as below: 
CO = 5x mean (OOn - ODb) 
Rs = (ODs - ODb )/CO 
The interpretation of results was as follows: 
- If RS < 0.8, result was interpreted as negative 
- If RS > 1.2, result was interpreted as positive 
- If RS from 0.8 - 1.2, result was interpreted as equivocal 
One-step real-time multiplex reverse transcription-peR 
The procedure for a one-step real-time multiplex RT-PCR that can identify i) OENVl, 
OENV3 and Equine Arteritis Virus (EA V), a positive-sense single-stranded RNA virus as an 
internal control or ii) OENV2, DENV 4 and EA V simultaneously was developed and validated. 
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The specific primers and probes for each DENV serotype and EA V are summarized in Table 2-2. 
A Iincarizcd plasmid containing the cloned target amplicon with a series of ID-fold dilutions was 
used as standard for the real-time RT-PCR. 
The preparation of the PCR master mix is described in Table 2-3. Then, 6J.l1 of RNA 
previously extracted from the patient's plasma, positive or negative controls, or standard DNA was 
added to the reaction. Amplification and detection was performed on a LightCycler 11 PCR 
machine (Roche. Germany). The DENV RNA was revcrse transcribed at 61°C for 10 minutes , 
followed by I cycle of dcnaturation at 95 0 C for 2 minutes and amplification steps consisting of 45 
cycles at 95 oC for 15 seconds and 600 C for 30 seconds, then a fluorescence measurement was 
made. 
Table 2-2. Specific primers and probes for each DENV serotype and EA V in the one-step 
I t' I . I I{T peR rea - Imc mu 'Iplex 
-
Pri mer/I)robc Pl'imer/Probe sequences (S'-3') Position Product size 
in base 
DENV 1- Forward ATCCATGCCCAYCACCAAT 9865 - 9883 
lOO 
DENV 1- Reverse TGTGGGTTTTGTCCTCCATC 9945 - 9964 
DENV2; Forward TCCATACACGCCAAACATGAA 9859 - 9879 
125 
DENV2- Reverse GGGA TTTCCTCCCA TGA n'cc 9963 - 9983 
DENV3- Forward TTTCTGCTCCCACCACTfTC 9591 - 9610 
118 
DENV3- Reverse CCATCCYGCTCCTTGAGA 9691 - 9708 
DENV4- Forward GYGTGGTGAAGCCYCTRGAT 9587 - 9607 
178 
DENV4- Reverse AGTGARCGGCCA TCCTI'CA T 9744 - 9764 
EA V- Forward CATCTCTTGCTTTGCTCCTTAG 1847 - 1868 
133 
EA V-Reverse CATCTCTTGCTTIGCTCCTTAG 1963 - 1980 
DENV I-Probe 5' (F AM) TCAGTGTGGAA TAGGGTITGGA T AGAGGAA 
3'(BIlQI) 
DENV2-Probe 5 '(FAM) AGGGTGTGGA TTCGAGAAAACCCA TGG 3 '(BHQ I) 
DENV3-Probe 5'(Cyan500) AAGAAAGTTGGTAGTTCCCTGCAGACCCCA 
3'(BIIQI) 
DENV4-Probe 5'(Cyan500rnCCCTCCTCTTYTTGAACGACATGGGAAAGGT 
G 3'(BHQ1) 
EA V-Probe 5 '(Cy5)CGCGCTCGCTGTCAGAACAACATT ATTGCCCACAG 
CGCG 3'(BIIQ3) 
Y stands jor C or T nucleotide, Rlor A or G. 
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Table 2-3. Components of one-step real-time multiplex RT -PCR master mix 
Reagents Working J'I/reaction 
concentration 
Mix of DENV 1 (or DENY2) Fw - Rev primers 20llM 1 
DENYl (or DENY2) probe 10llM 0.28 
Mix ofDENY3 (or DENY4) fw - Rev primers 20llM 1 
DENY3 (or DENY4) probe lOIlM 0.28 
Mix of EAY Fw - Rev primers 20llM 0.2 
EAV probe 10p.M 0.08 
Activator 1.4 
Enhancer 20X I 
RNA master mix 2.7 7.4 
1120 1.36 
Total 14 
The accompanying software of the Lightcyc1er 11 PCR machine, LightCyc1er® 480 SW 
1.5, was used to collect and analyse the one-step real-time multiplex RT-PCR results. The units of 
the RT·PCR are presented as copies/mt. The limit of detection (LOD) of each serotype is presented 
in the Table 2-4. Viraemia levels that were lower than the LOD were considered to be negative. 
Table 2-4. Limit of detection of one-step real-time multiplex RT -PCR assay 
- DENVl DENV2 DENV3 DENV", 
LOO (copies/reaction) 5 I 5 10 
LOO (copies/m I plasma) 300 60 300 600 
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2.8 Dlltn cleaning and treatment of missing values 
In addition to the quality checks that are used when the data are acquired, data discrepancy 
reports have been generated on an ongoing basis since the study commenced. In the first 
step, a team of experienced study doctors and I checked individual CRFs for the consistency 
and accuracy against the electronic databases. In the second step, we examined the whole database 
to identify outliers or implausible values, and then traced them back to the source documents 
for cross-checking if necessary. We also checked for duplicated records of the same patients 
and missing data. A complete case analysis was used because the amount of missing data was 
minimal. 
2.9 Descriptive and univariatc analyses 
Continuous data will be summarized as median (interquartile range), categorical data as 
absolute frequency and percentage. All candidate predictors will be summarized by diagnosis 
(confimled dengue vs. non-dengue). 
Univariate eflects of all candidate predictors on diagnosis will be estimated based on a 
logistic model and expressed as OR (95% Cl), p- value. Predictors have a statistically significant 
effect in the univariate analysis if the 95 percent confidence interval (95% Cl) does not include the 
value onc. 
Continuous variables will be properly scaled prior to the univariate analysis such that the 
OR is clinically interpretable. Continuous variables with a pronounced right-skewed distribution 
will be log2-transformed prior to analysis which implies that the OR now corresponds to the effect 
of a two-fold increase of the original variable. Natural cubic spline functions and generalized 
additive models will be used to assess whether there's a pronounced univariate non-linear 
relationship between a predictor and the outcome. 
Statistical software 
All statistical analyses will be performed using the latest version of the statistical software 
R (R foundation for statistical computing, Vienna, Austria). 
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Chapter 3 
CLINICAL AND VIROLOGICAL FEATURES OF PAEDIATRIC DENGUE IN 
SOUTHERN VIETNAM, 2010-2013 
Summary 
We described clinical and virological features of paediatric dengue cases in southern 
Vietnam in a large prospective cohort study. We used the new classification of WHO 2009 to 
include dengue shock syndrome, severe bleeding and organ failure in the category of severe 
dengue in data analysis. 
3.1. INTRODUCTION 
Community-based cohort studies have been critical in providing insights into dengue 
disease burden in endemic countries [34, 119-121]. Such studies infonl1 the natural history of 
dengue, and in particular the ratio of symptomatic and asymptomatic disease. llowever community 
cohort studies are not designed to provide deep detail on the clinical and virological characteristics 
of symptomatic cases, i.e. those who represent the greatest burden to health care services. Most 
prospective studies of symptomatic dengue have described inpatients alone and have not described 
the very large burden that is managed on an ambulatory basis. The scale of the ambulatory disease 
burden is important to understand for considering the economic burden of dengue and the rational 
assessment of individual and community level disease control interventions. In this study, we 
describe the characteristics of dengue cases I to 15 years old presenting to outpatient clinics at one 
of the seven hospitals in southern Vietnam. In detail, the objectives of this chapter are to describe 
the following points: 
a) prevalence, clinical features and outcomes of dengue in a cross-sectional study of acute 
fever in children 
b) the oscillations of DEN V serotypes according to geography and time in southern Vietnam 
c) the association between disease severity, plasma viral RNA concentration and NS I rapid 
test results 
d) the association between serological response in hospitalized dengue and plasma viral 
concentration, haematological and biochemical results 
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3.2. MATERIALS AND J\IETIIODS 
Details of study design, patient enrolment and data collection, including dengue diagnostics 
. 
and severity classification, were described in Chapter 2 (Materials and Methods). 
For each serotype, we compared plasma viral RNA concentration between dengue 
categories by using multiple linear regression to calculate odds ratios adjusted for day of illness at 
enrolmcnt. Logistic regression was used to evaluate the association between disease severity and 
NS I rapid tcst status in conjunction with day of illness at enrolment and infecting serotypes. The 
relationship between infecting serotypes and hospitalization adjusted for day of illness was 
assessed by using logistic regression. Differences between primary and secondary infection in 
tcnns of plasma viral RNA concentration, haemato-biochemical results were evaluated by using 
multiple linear regression to calculate adjusted odds ratios for day of illness at enrolment andlor 
infecting serotypes. 
We used the statistical software R version R v3.1.1 (R foundation for statistical computing, 
Vienna, Austria) for analyses. Significance was assigned at p < 0.05 for all parameters and was 
two-sided. 
3.3 IU:SULTS 
3.3.1 Study sl'tting and populntion 
Three hospitals, Children's Hospital ), Children's Hospital 2 and Hospital for Tropical 
Diseases in IICMC st3l1cd paticnt enrolment in Qct 2010. Children's Hospital 2 then stopped 
enrolment of patients since 2012 due to a lack of clinical resources in the outpatient setting. Other 
hospitals subsequently joined the study; Ticn Gi,ang Provincialllospital in the third quarter of20 11, 
Dong Nai Children's Ilospital and Long An Provincialllospital in the fourth quarter of2011 and 
Dinh Duong Provincial Hospital in the first quarter of 2012. Figure 3-2 shows the geographic 
locations of clinical study sites ill 110 Chi Minh city (Children's Hospital I, Children's Hospital 2 . 
and 1 lospital for Tropical Diseases) and Tien Giang, Dong Nai, Long An, Binh Duong provinces. 
At each hospital a triage system is in place to direct children with undifferentiated fevers to a 
selected number of outpatient rooms. Thcse rooms are often staffed by physicians on rotation from 
the Dcngue or Infcctious Disease dcpartment of each hospital. One of these outpatient examination 
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rooms at each hospital participated in patient enrolment. Each examination room is staffed by a 
physician and nurse and is open 8hrs per day (2x4hr shifts), 6 days per week. The case burden is 
large, with each physician seeing 60-80 patients per 4hr shift. 
The study profile of enrolment and patient outcome is shown in Figure 3-1. From Oct 2010 
to December 2013 a total of 7563 patients with fever of less than 72 hours were enrolled at one of 
the seven clinical study sites in southern Vietnam. Of these patients, 2 cases had missing values 
for haematology and 17 cases had missing values for biochemistry. Of 7544 patients who had 
complete haematological and biochemical results available, 2060 patients (27.3%) had laboratory-
confirmed diagnosis of dengue. The number of cases with severe dengue, dengue requiring 
parenteral fluids and uncomplicated dengue was 117 (5.7%), 156 (7.6%) and 1787 (86.7%) 
i 
respectively. Among the laboratory-confirmed dengue case population, the number of cases that 
were RT-PCR positive was 1954 patients (94.9%) of whom 897 (45.9%) were hospitalized. 
Proportions of RT-PCR positivity in the groups of severe dengue, dengue requiring parenteral 
fluids and uncomplicated dengue was 115/117 (98.3%), 149/156 (95.5%) and 1690/1787 (94.6%) 
respectively. 
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7563 patients enrolled 
7544 Patients had 
complete haematological 
and biochemical results 
available 
2060 laboratory-confirmed dengue: 
- 117 severe dengue 
- 156 dengue with i.v. fluids 
- 1787 uncomplicated dengue 
1954 RT-PCR positive cases had 
completed information for data 
analysis: 
- 115 severe dengue 
- 149 dengue with Lv. fluids 
- 1690 uncomplicated dengue 
19 Patients were excluded: 
- 2 Had missing values for haematology. 
- 17 Had missing values for biochemistry. 
5484 Patients were excluded because of 
being not dengue 
106 Patients were excluded because of 
unknown serotype and PCR results: 
- 2 severe dengue 
- 7 dengue with i.v. fluids 
- 97 uncomplicated dengue 
Figure 3-1. Flow chart showing patient enrolment and classification 
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Figure 3-2. Location of tudy sites 
The upper right corner map hOlls the geographic location a/Vietnam in the SOIl/hea / A ian region. 
The main map shows 1/0 hi Minh city (blue), Tien Giang (green), Dong ai 6
'
el/ow), Long An (pink) 
and Binh Duong (dark pink) province. Provinces are eparatecl by dark black boundaries. Locations 
0/ hospital are markecllVith red crosses. 
3.3.2 Ba eline characteri tics of the study population 
The baseline characteristics of all study participants, and of dengue cases only, stratified 
by study ite were hown in Table 3-1 and Table 3-2. The percentage of study participants with 
dengue was rea onably imilar across each of the sites, ranging from 21 % (Long An Provincial 
Ilospital) to 42% (hildren Hospital 2). The ranges of median age were 5-9 year for all study 
so 
participants and 8-11 years for dengue patients across study sites. Interestingly, at all study sites 
males slightly outnumbered females in the overall study population (% male: 53.6% - 58.8% 
across study sites) and also in the dengue case population (% male: 53.9% - 60.1 %). 
The majority of dengue patients were enrolled into the study on day 2 to 3 of illness. While 
at enrolment symptoms of vomiting (31.3% - 59.1%) and abdominal pain (13.3% - 27.2%) 
remained similar in dengue patients at all sites, physical signs of skin bleeding, flush and 
conjunctival injection showed a remarkably difference in percentages, particularly as low as 0% 
to 3.6% at DOli. TGII. ONII but as high as 15.9% to 76.0% at CHI and CH2. Quite possibly this 
reflects the subjective nature of these presentations, i.e. differences in clinical interpretation. 
Notably. symptoms of mucosal bleeding occurred in dengue patients during the first 3 days of 
illness at a very low rate from 0.6% to 5.9%, except for patients at CH2 (26.2%). Laboratory tests 
showed a low white blood cell counts (4.0 - 5.1 x I 03 cells/mm3) in dengue patients at all study 
sites. The hospitalization rate of dengue patients was from 32.6% - 36.2% (CHI, CH2) to 57.8% 
- 61.5% (111'0. LAII). 
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Table 3-1. Baseline characteristics of all study participants by site 
CHI CH2 HTD TGH DNH LAH BDH 
(N=2158) (N=657) (N=1311) (N=1037) (N=1015) (N=524) (N=842) 
Duration of study Jan-IO to Jan-IO to Jan-lOto Jun-I I to Nov-Il to Feb-12 to Feb-12 to 
conduction Dec-13 Dec-l I Dec-13 Dec-13 Dec-13 Dec-I3 Dec-13 
Age (years) 5 (3-8) 6 (3-9) 7 (5-1I) 6 (4-9) 9 (7-11) 8 (5-11) 6 (4-8) 
Sex: male 1184 (54.9) 386 (58.8) 758 (57.8) 589 (56.8) 574 (56.6) 305 (58.2) 451 (53.6) 
BMI 16.3 (14.3-18.8) 16.7 (14.9-18.9) 15.9 (14.3-18.1) 15.4 (14.1-17.2) 16.0 (14.4-17.9) 15.4 (14.3-17.3) 15.3 (14.1-17.1) 
Day of illness 
I 397 (18.4) 282 (42.9) 545 (41.6) 59 (5.7) 447 (44.0) 108 (20.6) 272 (32.3) 
2 1136 (52.6) 210 (32.0) 447 (34.1) 542 (52.3) 372 (36.7) 149 (28.4) 359 (42.6) 
3 625 (29.0) 165 (25.1) 319(24.3) 436 (42.0) 196 (19.3) 267 (51.0) 211 (25.1) 
Vomiting 580 (26.9) 361 (54.9) 584 (44.5) 436 (42.0) 397 (39.1) 167 (31.9) 275 (32.7) 
Abdominal pain 268 (12.4) 148 (22.5) 222 (16.9) 289 (27.9) 250 (24.6) 89 (17.0) 89 (10.6) 
Skin bleeding 258 (12.0) 134 (20.4) 11 (0.8) 7 (0.7) 11 (l.l) 18 (3.4) 0(0) 
Mucosal bleeding 79 (3.7) 112(17.0) 13 (1.0) 12 (1.2) 20 (2.0) 10(1.9) 12 (l.4) 
Flush 598 (27.7) 277 (42.2) 265 (20.2) 8 (0.8) 20 (2.0) 9 (1.7) 7 (0.8) 
Injection 171 (7.9) 451 (68.6) 124 (9.5) 3 (0.3) 5 (0.5) 6 (1.1) 6 (0.7) 
WBC (xlOl cells/mml ) 8.0 (5.3-11.8) 7.4 (4.9-10.8) 7.6 (5.2-11.1) 7.1 (4.7-10.5) 7.7 (5.6-10.8) 6.9 (4.6-9.4) 9.0 (6.1-12.4) 
Hct(%) 37 (35-39) 37 (36-40) 38 (36-40) 37 (35-40) 40 (38-43) 39 (37-41) 38 (36-40) 
PLT (xlOl cells/mm3) 229 (177-286) 227 (175-286) 224 (181-270) 231 (185-285) 218 (179-262) 221 (179-269) 234 (194-276) 
ALB (gII) 44 (42-46) 45 (43-46) 44 (42-46) 44 (42-46) 45 (43-47) 44 (42-46) 44 (42-46) 
AST (UIl) 43 (35-53) 46 (39-58) 41 (31-51) 43 (36-54) 45 (38-55) 45 (37-54) 43 (37-52) 
Hospitalization 230 (10.7) 121 (18.4) 429 (32.7) 225 (21.7) 232 (22.9) 133 (25.4) 134 (15.9) 
Laboratory-confirmed 540 (25.0) 279 (42.5) 391 (29.8) 283 (27.3) 277 (27.3) 109 (20.8) 181 (21.5) 
dengue 
Data are expressed as median (interquartile range) for continuous variables or frequency and percentage for categorical variables. CHI: Children's Hospital 1, 
CH:!: Children's Hospital 2, HID: Hospital for Tropical Diseases, TGH: Tien Giang Provincial Hospital, DNH: Dong Nai Children's Hospital, LAH: Long 
An Provincial Hospital, BDH: Binh Duong Provincial Hospital. 
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Table 3-2. Baseline characteristics of laboratory-confirmcd dengue patients by site 
CHI CH2 HTD TGH DNH LAH BDH 
(N=540) (N=279) (N=39 1 ) (N=283) (N=277) (N=I09) (N=181) 
Age (years) 9 (5-11) 8 (5-11) 10 (7-13) 8 (6-10) 10 (8-12) 11 (8-13) 8 (6-11) 
Sex: male 291 (53.9) 161 (57.7) 235 (60.1) 162 (57.2) 158 (57.0) 59 (54.1) 98 (54.1) 
BMI 17.0 17.4 16.6 15.4 16.6 16.4 15.8 
(14.7-19.7) (15.2-19.8) (14.8-18.9) (14.1-17.7) (15.2-18.9) (14.8-18.5) (14.1-18.3) 
Day of illness 
I 74 (13.7) 87 (31.2) 108 (27.6) 18 (6.4) 92 (33.2) 12 (11.0) 52 (28.7) 
2 246 (45.6) 94 (33.7) 147 (37.6) 124 (43.8) 118 (42.6) 27 (24.8) 82 (45.3) 
3 220 (40.7) 98(35.1) 136 (34.8) 141 (49.8) 67 (24.2) 70 (64.2) 4726.0) 
Vomiting 169 (3'1.3) 165 (59.1) 195 (49.9) 121 (42.8) 123 (44.4) 38 (34.9) 78(43.1) 
Abdominal pain 86 (15.9) 73 (26.2) 76 (19.4) 77 (27.2) 63 (22.7) 22 (20.2) 24 (13.3) 
Skin bleeding 137 (25.4) 99 (35.3) 9 (2.3) 6 (2.1) 8 (2.9) 14 (12.8) 0(0) 
Mucosal bleeding 32 (5.9) 73 (26.2) 5 (1.3) 5(1.8) 4 (1.4) 2 (1.8) 1 (0.6) 
Flush 191 (35.4) 149 (53.4) 119 (30.4) 4 (1.4) 10 (3.6) 7 (6,4) 5 (2.8) 
Injection 86 (15.9) 212 (76.0) 57 (14.6) 1 (0.4) 2 (0.7) 3 (2.8) 3 (1.7) 
WBC (xl03 cells/mm3) 4.7 (3.4-6.7) 5.1 (3.6-7.6) 4.9 (3.5-7.0) 4.3 (3.4-6.1) 5.6(4.1-7.3) 4.0 (3.2-5.5) 5.6 (4.0-7.4) 
Hct(%) 38 (36-40) 38 (36-40) 39 (37-40) 39 (36-41) 41 (38-43) 40 (38-41) 39 (37-40) 
PLT (x 1 03 cells/mm3) 169 (130-216) 192 (146-243) 180 (138-221) 182 (145-225) 180 (141-222) 170 (122-212) 192 (149-236) 
ALB (gII) 44 (41-46) 45 (42-46) 44 (42-46) 44 (43-46) 44 (42-46) 44 (41-45) 43 (41-45) 
AST(Ufl) 52 (40-76) 53 (41-69) 47 (38-62) 53 (43-73) 51 (42-69) 51 (42-70) 49 (41-62) 
Hospitalization 176 (32.6) 101 (36.2) 226 (57.8) 143 (50.5) 152 (54.9) 67 (61.5) 78 (43.1) 
Outcomes 
-Severe dengue 35 (6.5) 14 (5.0) 19 (4.9) 13 (4.6) 20 (7.2) 7 (6.4) 9 (5.0) 
-Dengue with i.v. fluids 35 (6.5) 22 (7.9) 44 (11.3) 43 (15.2) 4 (1.4) 2 (1.8) 6 (3.3) 
-Uncomplicated dengue 470 (87.0) 243 (87.1) 328 (83.9) 227 (80.2) 253 (91.3) 100 (91.7) 166 (91.7) 
Serotype 
-DENV-J 193 (38.4) 116 (42.8) 160 (42.7) 77 (29.4) 110 (40.7) 17 (17.0) 94 (54.3) 
-DENV-2 119 (23.7) 86 (31. 7) 100 (26.7) 61 (23.3) 39 (14.4) 18 (18.0) 21(12.1) 
-DENV-3 56 (11.1) 39 (14.4) 36 (9.6) 8 (3.1) 16 (5.9) 2 (2.0) 31 (17.9) 
-DENV-4 135 (26.8) 30 (11.1) 79 (21.1) 116 (44.3) 105 (38.9) 63 (63.0) 27 (15.6) 
Data are expressed as median (interquartile range) for continuous variables or frequency and percentage for categorical variables. The number of unknown serotype 
was 37,8,16,21,7,9 and 8 cases at CHI, CH2, HTD, TGH, DNH, LAH and BDH respectively. Dengue with i.v. fluids was hospitalized non-severe dengue with 
fluid infusion. Uncomplicated dengue included non-severe dengue and dengue without fluid infusion. CHI: Children's Hospitalt, CH2: Children's Hospital 2, HTD: 
Hospital for Tropical Diseases, TGH: Tien Giang Provincial Hospital, DNH: Dong Nai Children's Hospital, LAH: Long An Provincial Hospital, BDH: Binh Duong 
Provincial Hospital. 
53 
3.3.3 Characteristics and outcomes in dengue cases 
The final clinical outcome for dengue cases is summarised in Figure 3-3. Most of the severe 
dengue was due to DSS without any other severe complication. Of 117 severe dengue cases, 101 
patients were due to DSS, 10 patients had severe bleeding and 6 patients suffered from respiratory 
distress only. However 27 out of 101 DSS cases were accompanied by another severe 
manifestation such as severe bleeding (7 cases), respiratory distress (14 cases), or both (6 cases). 
A more detailed description ofthese subcategories including DSS, severe bleeding and respiratory 
distress in the group with severe dengue is presented in Table 3-3A, 3-3B and 3-3C. 
The characteristics of patients in the "dengue with i.v. fluids" group is described in Tablc 
3-4. The majority of intravenous fluid therapy was given on day 4 (24.8%), 5 (40.3%) and 6 (20.1 %) 
of illness. The reasons for giving infusion to these dengue patients were one or more of the 
following causes including haemoconcentration (59.7%), persistent vomiting (46.3%), anorexia 
(20.8%) and dehydration (18.1 %). Notably, of the 149 patients in the dengue with Lv. fluids group 
who had positive RT-PCR result, 32 (21.5%) required to switch from using crystalloid to colloid 
during the fluid replacement. 
54 
Shock (101) SC'\"CfC bleedirlg (23) 
Dengue With I. v. fluids Severe dengue 
(149/156 RT·PCR +) (llS/117RT.PCR+) 
Uncomplicated dengue 
(1690/1787 RT· PCR +) 
Labontory-eonfinned dtngue ~spWatory distress (29) 
Figure 3-3. Final outcome of dengue patients 
The quare p icture sholl's the Olltcomes of patients who were laboratOly-conjirmed dengue. The 
1I1111/ber of cases with severe dengue, dengue requiring parenteral fluids and uncomplicated 
(~ Jl1glle was JJ 7 (5. 7%), 156 (7. 6%) al7d 1787 (86. 7%) respectively. Proportions of Ri-peR 
po ifi"if), il1 the gro1lps of severe dengue, dengue requiring parenteral fluids and uncomplicated 
denglle was 115111 7 (98. 3%), f..I91156 (95.5%) and 169011787 (94.6%) respectively. The venn 
diagram shows J 17 el'ere dengue cases with shock (green), severe bleeding (pink) or respiratory 
di tre's (light yellow). 
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Table 3-3A. Characteristics of severe dengue - Dengue shock syndrome 
Shock (n=IOI) Median! n IQRI % 
Age 9 (7-11) 
Sex: Male 54 53.5 
BMI 
Day of illness at enrolment 
1 
2 
3 
Day of illness at shock 
3 
4 
5 
6 
7 
At enrolment 
- Vomiting 
- Abdominal pain 
- Skin bleeding 
- Mucosal bleeding 
- Flush 
- Injection 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Pulse pressure (mmHg) 
Pulse rate at shock (beat/m in) 
Pulse status 
- Undetectable 
- Weak 
- Strong 
Poor peripheral perfusion 
Re-shock 
WBC at enrolment (x 103 cells/mm3) 
Hct at enrolment (%) 
Hct highest (%) 
Day of illness at highest Hct 
PL T at enrolment (x 1 03 cells/mm3) 
PL T nadir (x 1 03 cells/mm3) 
Day of illness at lowest PL T 
ALB (g/I) 
AST (U/l) 
16.9 
15 
38 
48 
4 
28 
49 
18 
2 
66 
29 
17 
7 
31 
19 
95 
75 
20 
112 
4 
76 
21 
101 
18 
3.7 
40 
49 
5 
111 
39 
5 
43 
100 
(14.3-20.1) 
14.9 
37.6 
47.5 
4.0 
27.7 
48.5 
18.2 
2.0 
65.3 
28.7 
16.8 
6.9 
30.7 
18.8 
(90-100) 
(68-80) 
(20-20) 
(100-120) 
4.0 
75.2 
20.8 
lOO 
17.8 
(2.5-5.8) 
(38-42) 
(45-52) 
(4-5) 
(89-147) 
(25-62) 
(4-6) 
(40-45) 
(58-156) 
Data are expressed as median (interquartile range) for continuous variables or frequency and 
percentage for categorical variables. 
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Table J-JB. Characteristics of severe dengue - Severe bleeding 
Severe bleeding (n= I 0) Median/n IQRJ% 
Age (years) 8 (6-11) 
Sex: Male 8 80.0 
DMI 16.9 (15.0-18.8) 
Day of illness at enrolment 
1 0 0 
2 3 30.0 
3 7 70.0 
Day of illness at severe bleeding 
4 5 50.0 
5 3 30.0 
6 2 20.0 
At enrolment 
- Vomiting 8 80.0 
- Abdominal pain 3 30.0 
- Skin bleeding 2 20.0 
- Mucosal bleeding 1 10.0 
- Flush 3 30.0 
- Injection 2 20.0 
Sites of severe bleeding 
- GI bleeding . 9 90.0 
- Nose bleeding and venipuncture sites 1 10.0 
Required blood product transfusion 3 30.0 
Required local packing or compression 3 30.0 
WDe at enrolment (x 103 cells/mm3) 3.3 (2.7-5.4) 
Ilct at enrolment (%) 38 (37-42) 
I let highest (%) 44 (42-47) 
Day of illness at highest I let 4 (4-6) 
PL T at enrolment (x t 03 cells/mm3) 113 (89-158) 
PLT nadir (x 103 cells/mm3) 34 (19-74) 
Day of illness at lowest PL T 5 (5-6) 
ALD (gll) 44 (42-46) 
AST (UlI) 113 (63-140) 
Data are expressed as median (interquartile range) for continuous variables or 
frequency and percentage for categorical variables. 
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Table 3-3C. Characteristics of severe dengue - Respiratory distress only 
Respiratory distress only (n=6) Median/ n IQRI % 
Age (years) 4 (3-9) 
Sex: Male 4 66.7 
BMI 16.9 (14.4-21.1) 
Day of illness at enrolment 
1 0 0 
2 2 33.3 
3 4 66.7 
Day of illness at respiratory distress 
4 2 33.3 
5 16.7 
6 2 33.3 
7 1 16.7 
At enrolment 
- Vomiting 5 83.3 
- Abdominal pain 3 33.3 
- Skin bleeding I 16.7 
- Mucosal bleeding 1 16.7 
- Flush 2 33.3 
- Injection . 16.7 
Cause of respiratory distress 
- Pleural effusions and ascites 4 66.7 
- Pleural effusions only 1 16.7 
- Ascites only 16.7 
WBC at enrolment (x 103 cells/mm3) 4.5 (2.7-6.9) 
lIct at enrolment (%) 41 (39-43) 
I let highest (%) 48 (46-50) 
Day of illness at highest Het 4 (4-5) 
PLT at enrolment (x 103 cells/mm3) 74 (53-109) 
PLT nadir (x103 cells/mm3) 47 (36-57) 
Day of illness at lowest PL T 5 (3-5) 
ALB (g/l) 42 (40-44) 
AST (U/I) 130 (94-160) 
Data are expressed as median (interquartile range) for continuous variables or 
frequency and percentage for categorical variables. 
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Table 3-4. Characteristics of dengue patients with i.v. fluids 
Dcngue with i.v. tluids (n=149) Median! n 
Age (years) 9 
Sex: Male 
OMI 
Day of illness at enrolment 
1 
2 
3 
Day of illness at first infusion 
2 
3 
4 
5 
6 
7 
8 
At enrolment 
• Vomiting 
• Abdominal pain 
• Skin bleeding 
• Mucosal blceding 
.• Flush 
• Injection 
Reason for infusion 
• Ilacllloconcentration 
• Persistent vomiting 
• Anorexia 
• Dchydration 
Infusion by crystalloid only 
Infusion by crystalloid and colloid 
Total volume (ml/kg) 
woe at enrolment (x 10) cells/mm) 
I let at enrolmcnt (%) 
I let highest (%) 
Day of illness at highest Het 
PL Tat enrolmcnt (x 1 03 cells/mmJ) 
PL T nadir (x 1 01 cells/mm) 
Day of illness at lowest PL T 
ALB (gll) 
AST(UlI) 
75 
16.1 
29 
55 
65 
4 
13 
37 
60 
30 
4 
89 
48 
22 
9 
47 
33 
89 
69 
31 
27 
117 
32 
78 
4.4 
39 
44 
5 
147 
65 
5 
43 
58 
IQR/% 
(7·11) 
50.3 
(14.4-19.0) 
19.5 
36.9 
43.6 
2.7 
8.7 
24.8 
40.3 
20.1 
2.7 
0.7 
59.7 
32.2 
14.8 
6.0 
31.5 
22.1 
59.7 
46.3 
20.8 
18.1 
78.5 
21.5 
(24-113) 
(3.2-6.4) 
(37-41) 
(42·47) 
(4-6) 
(111·195) 
(38-95) 
(4-6) 
(41-46) 
(46-80) 
Data are expressed as median (interquartile range) for continuous variables or frequency and 
percentage for catcgorical variables. Dengue with i.v. fluids was hospitalized non-severe 
dengue with fluid infusion. 
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3.3.4 Natural history oftime to events in dengue cases 
For hospitalized cases, severe dengue patients had a longer illness history at enrolment 
compared to other groups with dengue and non-dengue (median day of illness (lQR): 3 (2-3) vs. 2 
(2-3) and 2 (1-3) days respectively). Patients with severe dengue were also hospitalized sooner 
after enrolment compared to those with dengue and non-dengue (median days from enrolment to 
admission (lQR): 1 (0-2) vs. 1 (1-2) and 2 (0-3) days respectively). (Table 3-5). The median day 
of illness at severe complications was 5 (lQR: 4-5). 
Table 3-5. Relationship between day of illness, day of hospitalisation and onset of severe 
signs/symptoms in study participants 
Severe dengue Dengue Non-dengue p 
(N=1l7) (N=826) (N=561) 
Day of illness at 3 (2-3) 2 (2-3) 2 (1-3) <0.001 
enrolment 
1 15 (12.8) 159 (19.2) 179 (31.9) 
2 43 (36.8) 327 (39.6) 207 (36.9) 
3 . 59 (50.4) 340 (41.2) 175 (31.2) 
Days from enrolment to 1 (0-2) 1 (1-2) I (0-2) <0.001 
hospital admission 
0 30 (25.6) 202 (24.5) 162 (28.9) 
34(29.1) 286 (34.6) 255 (45.5) 
2 29 (24.8) 187 (22.6) 88 (15.7) 
3 14 (12.0) 102 (12.3) 31 (5.5) 
4 9 (7.7) 35 (4.2) 20 (3.6) 
5 1 (0.9) 12 (1.5) 4 (0.7) 
6 2 (0.2) 1(0.2) 
Day of illness at first 5 (4-5) 
onset of severe 
complications 
3 4 (3.4) 
4 35 (29.9) 
5 53 (45.3) 
6 22 (18.8) 
7 3 (2.6) 
Data are expressed as median (interquartile range) for continuous variables or frequency and 
percentage for categorical variables. P- values were given by Chi-square tests. 
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3.3.5 Temporal and spatial distribution ofDENV serotypes 
DENV-l and DENV-4 accounted for 39% (767/1954) and 28% (555/1954) respectively of 
all RT-PCR dengue positive cases. DENV-2 was identified in 444 (23%) and DENV-3 in 188 
(10%) patients. The distribution of dengue serotypes by sites during the entire study period is 
shown in Table 3-2 and Figure 3-4. In HCMC, DENV-l and DENV-2 were the predominant 
serotypcs in 20 I 0 and 2011. Interestingly, 2011 saw the emergence ofDENV-4, first in Tien Giang 
Provincial Hospital but subsequently in all study sites during 2012/13 such that by 2013 it was the 
2nd most commonly dctected serotype in that year. On the contrary, a gradual but steady continuous 
decrease in the prevalence ofDENV-2 took place at all study sites from 2011 to 2013. The number 
of laboratory-confirmed dengue cases in 2013 was also lowest compared to that of previous years 
and this was consistent with Ministry of Health surveillance data indicating 2013 was a relatively 
low year for dengue case burden (See Figure 1-5 in the Introduction). These data suggest that 
Vietnam is a dengue endemic country that experiences the co-circulation of four viral serotypes, 
each of which may differ in their epidemic potential. 
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Figure 3-4. Numbe.· of dengue cases and infecting serotype, stratified by ho pital and year. 
X-axis: time, Y-axis: number of dengue cases. CHI: Children's Ho!;pital 1, 112: hildren's 
Hospital 2, HTD: Hospital for Tropical Diseases, TGH: Tiel/ Giang Provincial Ho pital, DNH: 
Dong Nai Children's Hospital, LAN- Long All Provincial Hospital, BDH: Binh Duong Provincial 
Hospital. CH2 stopped enrolment of patients since 2012. TGH started patient enrolment in the 
third quarter of2011 ,. DNH and LAH started patient enrolment in the fourth quarter of2011; BDH 
started patient enrolment in the first quarter of 2012. 
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3.3.6. Relationship between clinical outcome and DENY serotype, plasma DENV RNA concentration and NSl rapid test results 
at enrolment 
Table 3-6. Relationship between DENV serotype and disease outcome 
Severe dengue Dengue with i.v. fluids Hospitalized dengue 
(N=llS) (N=149) (N=897) 
n(%) OR (9S%CI) p n (%) OR (95%CI) P n (%) OR (95%CI) P 
DENV-l (N=767) 38 (33.0) 0.8 (0.5, 1.3) 0.352 62 (41.6) 1.5 (0.9,2.3) 0.184 367 (40.9) 1.0 (0.8, 1.3) 0.785 
DENV-2 (N=444) 37 (32.2) 1.4 (0.9-2.3) 0.058 47 (31.5) 2.1 (1.3,3.3) 0.028 199 (22.2) 0.9 (0.7, 1.2) 0.696 
DENV-3 (N=148) 6 (S.2) O.S (0.2, 1.2) 0.416 9 (6.0) 0.8 (0.4, 1.8) 0.583 68 (7.6) 0.6 (0.4, 0.9) 0.034 
DENV-4 (N=S5S) 34 (29.6) 31 (20.8) 263 (29.3) 
Reference group: DENY-4 
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Comparisons of plasma DENV RNA concentrations between clinical outcome categories and 
stratified by serotype were done by using logistic regre ion adju ted for day of illnes . Generally 
apart from DE V-3 where the sample ize wa limited, pia ma R A iral concentration \ ere 
sign ificant ly higher in severe d ngue ca e than in uncomplicated dengue ca e for any erot pes 
(all adjusted p-values <0.05) (Figure 3-5). The odds of having e ere dengue incr a ed by 1.3-1.7 
times for each 10-fold higher DENY R A concentration a compared to patient \ ith 
uncomplicated dengue (Table 3-7) and thi \ a tati tically ignificant for D -NV-J, -2 and -4. It 
means that vira l concentration i associated with dengue e erity. 
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Figure 3-5. Plasma viral RNA concentration by di ea c c erity. 
Box and whisker plots of pIa fila viraemia level il1 enrolment samples represent median, 25,11 and 
75'11 percentile, minimum and maximum of the data by DE V erotypes and severity. P-values 
were adjusted for day of iflne . The number of ca e in each dengue category by different 
infecting ·erotypes are shown on the X-axis. 
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Table 3-7. Relationship between plasma viraemia and dengue severity stratified by 
serotypes 
Severe dengue 
(N=) IS) 
Dengue with i.v. 
fluidsa 
Uncomplicated dengueb 
(N=1690) 
(N=149) 
OR (9S%CI)C 
DENV-I 1.3 (1.1-1.6) 1.7 (1.4-2.1) 
DENV-2 lA (1.1-1.8) 1.2 (0.9-1.5) 
DENV-3 1.7 (1.0-3.0) I 04(0.9-2.2) 
DENV-4 1.6 (1.2-2.2) 1.3 (0.9-1.8) 
• Ocngul! with i.v. Iluids was hospitalized non-severe dengue with Iluid infusion. 
b Uncomplicated dcngue includcd non-severe dengue and dengue without fluid infusion. 
1 
) 
C OR: Adjusted odd ratios for day of illness to assess the odds of having severe dengue or dengue with i.v. 
fluids for each I Q-fold higher DENY RNA concentrations as compared to patients with uncomplicated 
dengue. Reference group = Uncomplicated dengue. 
3.3.7 Relationship between disease outcome and NSl rapid test results at enrolment 
The detection ofNS 1 was strongly associated with disease severity. The odds of belonging 
to the severe dengue or dengue with i.v. fluids groups ~ncreased by 2.9 (9S%CI: 1.7-5.0) and 204 
times (95%CI: 1.5-3.7) respectively for dengue patients who were NS I rapid test positive as 
compared to dengue patients whose NS I rapid test was negative (Table 3-8). 
Table 3-8. NS 1 rapid test by disease severity 
NS 1 Positive (n, %) 
OR (9S%CI)d 
Severe dengue Dengue with 
(N=)IS) i.v.fluidsa 
95 (82.6) 
2.9 (1.7-S.0) 
(N=149) 
120 (80.5) 
204 (1.S-3.7) 
Uncomplicated 
dengueb 
(N=1690) 
I 187 (70.2) 
) 
a Dengue with Lv. lluids was hospitalized non-severe dengue with fluid infusion. 
OFIC 
(N=5484) 
32 (0.7) 
b Uncomplicated dengue included non-severe dengue and dengue without fluid infusion. 
C OFf: Other febrile illnesses. 
d OR: Adjusted odd ratios for day of illness and serotype. Reference group = Uncomplicated 
dengue. 
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3.3.8 Relationship between serological response in hospitalized dengue with DENV serotype, 
plasma viral concentration and laboratory results. 
Classification of serological responses (i.e. primary versus secondary) was only possible 
for hospitalized patients as only these participants had paired plasma specimens for serological 
investigations. Of the 897 hospitalized dengue cases with infecting serotypes identified by RT-
PCR, 204 (22.7%) were primary and 647 (72.1 %) were secondary infection while in the remaining 
46 cases (5.1 %) the results of serological diagnostics for immune status were inconclusive. Nighty-
three % of the severe dengue cases and 79.9% of the "dengue with i.v. fluids" group were 
secondary infections respectively (Table 3-9). By serotype, secondary infections were most 
strongly associated with DENV-2 and DENV-4, with 87.9% and 88.6% respectively being 
secondary infections. For DENV-l and DENV-3, there was a more balanced mix of primary and 
secondary infections, with 54.8% and 55.9% respectively being secondary infections. Figure 3-6 
summarises the serological profile according to serotype. 
Table 3-9. Relationship between serological response and disease outcome 
Severe dengue Dcngue with i.v. Uncomplicated 
fluids dcngue 
(N=115) (N=149) (N=633) 
Primary infection (n, %) 6 (5.2) 25 (16.8) 173 (27.3) 
Secondary infection (n, %) 107 (93) 119 (79.9) 421 (66.5) 
Inconclusive (n, %) 2 (1.7) 5 (3.4) 39 (6.2) 
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Figure 3-6, cl'ological rcsponse according to dengue serotype 
Among ho pitalized dengue patients with the same duration of illness history there was no 
di fference in plasma viral concentration between primary and secondary infection in overall as 
well a in tho e duo to DENY- I, DENY-2 and DEN"v-3 (all adjusted p-values >0.05). However 
D NY-4 infl ctod patient had significant higher plasma viraemia levels in secondary than primary 
infecti n (median and interquartile range (IQR), 7.0 (6.1-7.8) vs. 6.7 (5.4-7.3) log lOcopies/ml 
re peclively, adju ted p=O.O 13) (Table 3- 10). 
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Table 3-10. Plasma viral RNA concentration vs. serological response in hospitalized dengue 
cases 
All hospitalized Primary Secondary p 
dengue a infection infection 
Median (IQR) Median (lQR) Median (lQR) 
N N N 
All serotypes b 7.4 (6.4-8.4) 7.8 (6.6-8.7) 7.3 (6.3-8.2) 0.124 
851 204 647 
DENV-l b 8.0 (6.8-8.8) 8.1 (6.8-8.9) 8.0 (6.8-8.7) 0.748 
340 139 201 
DENV-2b 7.2 (6.3-8.0) 7.6 (6.1-8.2) 7.2 (6.3-8.0) 0.559 
190 15 175 
DENV-3 b 7.8 (6.4-8.7) 7.4 (6.6-9.5) 7.8 (6.3-8.7) 0.935 
65 27 38 
DENV-4 b 6.9(6.1-7.7) 6.7 (5.4-7.3) 7.0 (6.1-7.8) 0.013 
256 23 233 
a 46 hospitalized patients were excluded, of which the number of DENY-I, DENV-2, DENY-3 and DENY-4 
serotype were 27, 9, 3, and 7 cases respectivcJy, because of having inconclusive serological responses. 
b log I Ocopies/ml 
P -values were adjusted for day of illness to compare viraemia between primary and secondary infection. 
Compared to those with primary infections, at enrolment patients with secondary infections 
had lower median (IQR) albumin levels (43 (41-45) vs. 44 (42-47) gll), white blood cell counts 
(4.4 (3.1-6.3) vs. 5.0 (3.5-6.8) xl03 cells/mm3), platelet counts (146 (109-184) vs. 181 (145-217) 
xl03 cells/mm3), higher AST (59 (45-85) vs. 49 (40-60) V/I) and higher years of age (10 (7-12) vs. 
(8 (6-10) years) (all adjusted p-values <0.05). Patients with secondary infections also had 
significantly lower median platelet nadir during hospitalization than patients with primary 
infections (62 (25-91) vs. 95 (46-138) xl03 cells/mm3) (Table 3-11). These data suggest that 
secondary infection have more severe manifestations compared to primary infection. 
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Table 3-11. Serological response vs. haematology, biochemistry in hospitalized dengue 
cnses 
Primary infection Secondary infection 
(N=204) (N=647) 
At enrolment 
Sex: male (n, %) 122 (59.8) 335 (51.8) 
Age (years) 8(6-10) 10(7-12) 
ALIl (g/I) 44 (42-47) 43 (41-45) 
AST (UlI) 49 (40-60) 59 (45-85) 
WIlC (x 103 cells/mm3) 5.0 (3.5-6.8) 4.4 (3.1-6.3) 
I let (%) 39(37-41) 40 (37-42) 
PLT (x 103 cells/mm3) 181 (145-217) 146 (109-184) 
Dllrin!: 11O.\pilaIiZ(llion 
I let highest (x 103 cells/mm3) 41 (38-43) 43 (39-45) 
PLT nadir (x103 cells/mm3) 95 (46-138) 62 (25-91) 
Data ar!! expr!!ssed as median (interquartile range) for continuous variables. 
3.4 DISCUSSION 
p 
0.045 
0.011 
0.001 
<0.001 
0.041 
0.142 
<0.001 
0.280 
<0.001 
This large, prospective, outpatient-based study of dengue in southern Vietnam has provided 
a relatively unbiased clinical and virological profile of the disease burden seen 'by local health 
services. The results confirm that DSS is the commonest severe complication of dengue in children 
in this setting and that it occurs in -5% of cases. The results also highlight the burden of dengue; 
45.9% of all RT-PCR positive dengue cases in this study were hospitalized at some point in their 
illness and 13.5% required therapeutic interventions because of severe dengue or dengue with Lv. 
fluids at some point in their hospitalization. For the first time we have estimated, with a high level 
of precision, the contribution that increased (early) DENV viraemia, or the presence of a detectable 
NS I alltigenaemia, has on the likelihood of developing severe dengue. Furthennore, we have been 
able to describe serotype-specific differences in risk of clinical complications and in the profile of 
the disease burden. For exainple, primary infections with DENV-2 and DENV-4 contributed a 
negligible amount to the hospitalized disease burden during the study period. Our findings were in 
agreement with previous publications suggesting that DENV-2 appears to be significantly 
associated with more severe dengue compared to other serotypes [110, 122]. 
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The great majority of dengue cases in this study were aged from 5 to 13 years. 
Approximately 45.9% of dengue cases were hospitalized (versus 10.2% of children with other 
febrile illness). Children who were hospitalized with secondary dengue were older than children 
hospitalized with primary infection. The age of the dengue case burden in this study (median age 
9 (lQR: 6-11) years) is entirely consistent with previous hospital-based data in this setting between 
2000-2009. This indicates that despite substantial socioeconomic development in southern 
Vietnam in the last 15 years there is no evidence that the force of infection is declining. Vietnam's 
dengue control program depends up the surveillance system including vector control, virological 
monitoring and case management. Probable explanations for why the national control program has 
failed to reduce the number of infected patients are the presence of unnoticed infection in the 
community, changes of virus transmission dynamics and the absence of effective interventions to 
eliminate all breeding grounds to mosquito. The difficulty in controlling dengue using existing 
tools underscores the need for vaccines and other novel control methods (e.g. Wolbachia). 
Most of the early clinical manifestations of dengue are nonspecific until the disease 
progresses to severe complications or resolves spontaneously without complications. Ofnote, there 
was considerable variation in the incidence of physician-reported signs such as skin-bleeding, flush 
and conjunctival injection in dengue patients. This highlights the SUbjective nature of the 
manifestations. Eighty-five percent of dengue cases would have met the WIIO 2009 case definition. 
The dengue case definition in Vietnam is also the same as that from WIIO and is now widely used 
throughout the country. The next chapter will consider whether any of the early clinical or 
laboratory features of dengue can be employed in a diagnostic algorithm to further enhance early 
diagnosis. 
DSS represents the commonest severe dengue complication in children followed by 
respiratory distress and severe bleeding. This finding is similar to previous reports which showed 
severe dengue in children was mainly due to DSS rather than severe haemorrhage [36, 123]. Of 
note, while confirmed dengue patients with DSS or severe bleeding occurred at older age (median: 
8-9 years) those with respiratory distress occurred at younger age (median: 4 years). This is 
because the compensation of the respiratory system in young children is fragile and more 
susceptible to being deteriorating in case of plasma extravasation and third-space fluid loss. Most 
respiratory distress was due to pleural effusion alone or in combination with ascites and sometimes 
due to overhydration in fluid replacement. Most severe bleeding was due to gastrointestinal 
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bleeding. The great majority (93%) of severe cases had secondary. infections and DENV-2 was 
proportionally more common in severe cases than other serotypes. Watts et al found that secondary 
DENV2 infections with the Asian genotype were more likely to cause severe dengue than the 
American genotype [124]. It has been hypothesized that more efficient DENV-2 replication in 
primed hosts confers enhanced pathogenicity [110]. The increase in susceptibility to secondary 
infection could be explained by the co-circulation of 4 dengue serotypes in Vietnam with 
sequential replacement of the dominant serotype [20, 125]. The majority of hospitalized dengue 
patients were due to secondary infection accounting for 76% (647/851) in our study which was 
similar to other reports in Southeast Asia [55, 119, 126, 127]. We found that haematological and 
biochemical values indicated a more severe status in patients with secondary infections, including 
lower albumin levels, white blood cell counts, platelet counts and higher AST at enrolment 
together with lower platelet nadir during hospitalization as compared to patients with primary 
infections. These findings agree to other studies and are consistent with the antibody dependent 
enhancement theory as well as its role in pathogenesis [56]. Libraty and Duyen et al. reported the 
association of secondary infection and thrombocytopenia [111, 128]. Other colleagues in the 
Caribbean and Pakistan found the correlation between elevated serum enzymes levels, d~creased 
platelet count and. secondary dengue infection '[129, 130]. The reason for lower albumin in 
sccondary than in primary infection is explained by a greater extcnt of plasma leakage in secondary 
than in primary infection. 
or note, no dengue cases died in this study. This is reflective of the overall low mortality 
rate for dengue in Vietnam, estimated at below 1/1000 hospitalised cases. This low case mortality 
has arisen because of the skills and experience of physicians managing dengue cases in southern 
Vietnam and clear hospital guidelines on fluid management. In this study the main indications for 
parenteral fluid infusion included haemoconcentration and persistent vomiting, both of which are 
considered dengue warning signs according to WHO guidelines [I]. Persistent vomiting can 
exacerbate haemoconcentration, a manifestation of plasma leakage which can result in 
hypovolemia and DSS [131]. Our study showed that colloids were also used in volume 
replacement in combination with crystalloids. All therapeutic modalities to dengue infection are 
symptomatic as regards DSS or severe bleeding by replacement of fluid loss with 
crystalloid/colloid solutions or blood-derived products. Consequently, it is recommended by WHO 
that dengue patients with vasculopathy should be given carefully-titrated crystalloid fluid to 
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maintain hemodynamic stability. Colloids are recommended when crystalloid fluid infusion has 
not elicited the desired clinical response [I, 49, 51, 132, 133]. 
The Ministry of Health dengue surveillance program showed that DENV-I and DENV-2 
were the predominant serotypes in southem Vietnam between 2003 and 2011 [20]. Our study 
described a temporal change in the distribution of dengue serotypes among infected patients 
presenting to outpatient clinics. DENV -4 increased remarkably from 2011 to 2013 firstly at Tien 
Giang Provincial Hospital then to all other hospitals to replace DENV-2 and became the second 
most prevalent infecting serotype. The presumed drivers of major changes in serotype prevalence 
in endemic areas such as southern Vietnam are the introduction of new lineages with greater 
epidemic potential or the interserotypic immune reactions in the population. There is no evidence 
about the relationship between climate change and variation in the pattern of dengue serotype. 
Instead, climate change might affect disease transmission, e.g. changes to the force of infection 
that could lead to more or less frequent oscillations in serotypes. Interestingly, this temporal 
change of serotypes was accompanied by a sharp decline in the number of infected cases in the 
following year, 2013. This observation is at odds with the general view that major serotype changes 
in endemic settings.are often associated with increased incidence [134-136]. Perhaps DENV-4, as 
suggested by others [137], is less "virulent" in its epidemic potential, i.e. it has a lower RO than 
other serotypes. This might be because it is less infectious for mosquitoes, as suggested by previous 
human-to-mosquito transmission studies by our group in Vietnam [138]. We note however that 
DENV-4 can cause severe dengue; the proportion of all DENV-4 cases that evolved to "severe" 
was similar to DENV-I, 2, 3. 
We also found that early plasma viral RNA concentrations are positively associated with 
disease severity, as suggested by previous studies [110, Ill, 139]. Plasma viraemia can be 
considered as a proxy for virus infection oftissues, which enhances the immune response in dengue 
infection leading to severe disease. Yet, plasma RNA viraemia concentrations may not be a good 
surrogate for the titre of infectious virus, because the assay measures nucleic acid only. With 
respect to describing the relationship between early viraemia and outcome, this study is unique in 
the sample size of the study population, the representation of all four serotypes and the breadth of 
clinical outcomes, from ambulatory to severe cases. Furthennore we have given precision to the 
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degree of association between viraemia and severe dengue, with odds ratios of 1.3-1.7 for DENV-
1-4. Yet whilst significant, the strength of the association between early viraemia level and severe 
disease was not particularly high. This underscores the complex nature of dengue pathogenesis; 
the magnitude of the systemic viral infection (of which we assume viraemia to be a proxy) is only 
one aspect driving the complex syndrome. Other aspects, e.g. host predisposition [21, 63], 
flavivirus immune status [140, 141] and even clinical management [142, 143] probably all 
contribute to the final clinical outcome independently of viraemia level. 
It is also acknowledged that viraemia is positively associated with NS I levels in plasma 
[109, 111, 144]. The results ofNS I rapid tests again depends on NS 1 antigenaemia [145]. Among 
the nonstructural proteins of dengue virus, NS 1 is highly conserved and hypothesised to play a 
role in the severity of the disease, as increased concentration of soluble NS 1 in serum correlates 
with viracm ia levels and disease severity [109, 146]. Therefore, NS 1 response is supposed to be 
strongly correlated with disease severity as reported in our results. However, the test has some 
limitations regarding the fact that the sensitivity of the test was reportedly lower in DENV-2-
infected patients than DENV-I, DENV-3 or DENV-4 infected patients [63, 96, 98] and the 
sensitivity was also lower in those with secondary infections relative to prima~ infections [63,93, 
96-98, 116]. 
In this present study, after controlling for day of illness at enrolment, we did not find a 
correlation between plasma viral RNA concentration and serological response (primary vs. 
secondary) amongst hospitalized dengue patients. The only infecting serotype that had higher 
plasma viraemia in secondary infection than in primary infection was DENV-4. This finding was 
similar to Murgue's et al [147], but not consistent with other studies on DENV-l or DENV-2 
infections [110, 128, 148]. It m ight be possible because of the difference in classifying primary 
and secondary infections. Vaughn, Yeh and Duyen et al. defined secondary infection as a clear 
increase in IgO level by day 5-7, while in our present study we classified serological response 
based on IgM seroconversion and the presence oflgG. In our study, a positive dengue IgG of either 
the acute or convalescent blood sample at discharge was defined as "probable secondary infection"; 
otherwise that both the two samples were negative for dengue IgO was considered as "probable 
primary infection". Thus it is possible that a small number of primary cases have been misclassified 
as secondary cases. I fowever we believe the number of misclassification will be small because of 
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the 897 hospitalized patients, convalescent samples were collected on day 6, 7, 8, 9 and 10 of 
illness and accounted for 92% (825 cases), 5% (45 cases), 1.5% (13 cases), 1% (9 cases) and 0.5% 
(5 cases) respectively. In our results, the "probable primary infection" group only accounted for 
17/897 (1.9%) of hospitalized dengue patients, consistent with secondary infection being an 
important epidemiological risk factor. 
The other explanations are DENV-2 infections were not common among hospitalized 
dengue patients in our study and particularly DENV-2 primary infections were rare. 
In brief, this study provided a comprehensive description of DEN V infection in Vietnamese 
children via a large, prospective cross-sectional study in outpatient departments. We documented 
clinical manifestations, laboratory findings and virological characteristics at enrolment and for a 
subset, during hospitalization. We measured with some precision the association between NSl 
antigenaemia and viraemia with disease severity. Surprisingly, we found no association between 
early viraemia levels and secondary infection status. The results of this study will assist clinicians, 
epidemiologists, public health officials and scientists to implement intervention measures on 
treatment, control and clinical trials to achieve the aim of reducing the incidence rate, mortality 
rate and case fatality rate of dengue. The next two chapters will employ data from this prospective 
study to a)- devise algorithms to make an early diagnosis of dengue and b) devise algorithms to 
predict patients at risk of severe dengue. 
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Chapter 4 
A NOVEL DIAGNOSTIC CLASSIFIER FOR THE EARLY DIAGNOSIS OF DENGUE 
Summary 
Dengue is a common, potentially life-threatening disease in the tropical world. We 
developed a clinically intuitive algorithm that can be used alone or as an adjunct to dengue NSI 
rapid tests for improved early diagnosis of dengue. We demonstrate that the early diagnosis of 
dengue can be enhanced beyond 'the current standard of care using a simple evidence-based 
algorithm. The results should support patient ~anagement and clinical trials of specific therapies. 
This chapter was submitted and published on the journal PLOS Neglected Tropical 
Diseases and can be found at 
http://journals,plos,org!plosntds/article?id=1 0.1371 Ijoumal.pntd.0003638 
4.1 INTRODUCTION 
Dengue is an acute, systemic viral infection and a public health problem in the tropical 
world [1]. The aetiological agents of dengue are any of the four dengue viruses (DENV-I-4). In' 
endemic countries it is common for ail four DENV serotypes to co-circulate. Late-stage trials of 
a dengue vaccine with intermediate efficacy have recently been reported, offering hope of a public 
health intervention [6, 149]. 
The World Health Organisation (WHO) has a stated goal of reducing global dengue 
mortality by 50% by 2020 [1]. Improvements in case diagnosis and management will be central to 
achieving this aim. Significant loss of intravascular plasma volume leading to hypovolemic shock 
(dengue shock syndrome (DSS», usually between the 4th_6th day of illness, is the commonest life-
threatening complication of dengue [1,150]. It's widely held that the case-incidence ofDSS can 
be reduced via careful monitoring and the judicious use of parenteral fluids to maintain an adequate 
intravascular volume [1]. Ideally, this case management approach is enabled because the attending 
physician had made an early diagnosis and thus alerted clinicians, nurses and family caregivers to 
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the signs and symptoms suggestive of clinical worsening. Additional benefits of an early diagnosis 
include support to community level public health interventions and improvements in the sensitivity 
of case surveillance systems and disease burden estimates. Furthermore, it is likely that the 
therapeutic window of opportunity for a dengue antiviral drug lies in the first 48-72 hours of illness 
[151]. Thus, programmatic use of therapeutic interventions in the future will likely go hand in hand 
with strategies for early diagnosis. 
Yet there are numerous challenges for busy primary care clinicians in making a diagnosis 
of dengue in the first few days of illness. Rapid lateral flow tests, based on the detection of the 
viral NS 1 antigen, are available in some settings and can provide a confirmatory diagnosis [96,98, 
152]. The diagnostic performance of the WHO dengue case definition, which relies on non-specific 
signs and symptoms that overlap with other infectious diseases, is unknown in the first few days 
of illness [1]. Potts et al concluded that more prospective studies were needed to construct a valid 
and gcneralizablc algorithm to guide the differential diagnosis of dengue in endemic countries 
[153]. To this end, several prospective studies have described the creation of classifiers for the 
diagnosis of dengue [32, 154, 155]. However none of these studies have exclusively focused on 
paediatric fever cases presenting to primary care facilities with short illness histories, a very 
common scenario in dengue endemic settings. Against this backdrop, the purpose of the current 
study was to prospectively derive a dengue diagnostic algorithm from routinely clinical and 
laboratory findings in paediatric patients with <72 hours of illness history and compare this 
approach against the diagnostic performance of a leading NS 1 rapid test (BioRad NS 1 Ag STRIP) 
in the same patients. The results provide pragmatic methods to enhance the early diagnosis of 
dengue in primary care settings. 
4.2 MATERIALS AND METHODS 
Details about study design, patient enrolment, data collection and variable definitions were 
presented in Chapter 2 (Materials and Methods). 
Enrichment ofNSl 
Plasma samples were enriched for proteins with molecular weight> lOOkDa using Arnicon 
filtration units (MilIipore). Briefly, 200J.l1 of plasma was concentrated to -30J.l1 and then tested 
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in the Platelia NS 1 ELISA. All concentrated samples were tested in parallel with an aliquot of 
the original plasma samples and the filtrate (containing proteins with molecular weight 
<100kDa). 
Strategy for developing the multivariable prediction models 
Logistic regression was used for the development of the diagnostic algorithm [156, 157]. 
Continuous laboratory variables with a right-skewed distribution will be log2-transformed prior to 
analysis. Natural cubic spline functions and generalized additive models will be used to assess 
non-linearity. Potential interactions between candidate predictors will be assessed by comparing 
the models with and without interaction terms (e.g. appropriate likelihood ratio tests for 
interaction). Interaction plots will also be used to visualize whether interactions warrant inclusion 
into the full model. 
A detailed assessment of the model assumptions oflinearity and additiyity was performed 
(supplementary statistical appendix). All pre-defined candidate predictors listed in Supplementary 
Table 4-1 and significant interaction terms were included in the full model. The model was then 
simplified using step-wise backwards selection using Akaike Information Criterion (AIC) and 
stability selection [158]. Alternative statistical models such as classification and regression trees 
(CART) and random forests (RF) were also investigated in order to find an optimal diagnostic 
algorithm [159, 160] . 
. Evaluation of model accuracy and performance 
The performance of the model was assessed with respect to discrimination (receiver operating 
characteristic curves (ROCs) and area under the ROC curve (AVC», calibration (calibration plots 
and calibration intercepts and slopes), and standard accuracy criteria of binary diagnostic tests 
(sensitivity, specificity, negative and positive predictive values). We selected the cut-offpoint to 
classify a patient as dengue positive at a predicted risk of dengue of ~33.3%, corresponding to 
assuming that the "cost" of missing a true dengue patient is twice as large as the cost of a false-
positive [157]. 
Model validation 
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To avoid over-optimistic estimates of model accuracy and performance due to model 
derivation and evaluation on the same dataset, all accuracy measures were corrected for optimism 
by validation. Validation was performed for the whole model development process including 
variable selection. Two validation schemes were employed to mimic external validation: 
a) "Ieave-one-site-out cross-validation", i.e. repeatedly developing the algorithm on all but 
one site and validation on the left-out site 
b) Temporal validation with pl'.tients recruited before 15 June 2012 as the training set and 
patients recruited thereafter as the evaluation set [156]. 
Presentation of the final model 
The final logistic model will be presented in a standard way as OR [95% Cl] and p-values 
for all coefficients. It will then be simplified to a nomogram for direct clinical use. 
All statistical analyses were performed using the statistical software R v3.1.1 (R foundation 
for statistical computing, Vienna, Austria) and its companion packages c060 version 0.2-3 (for 
stability selection), randomForest version 4.6-7 (for random forest) and rpart version 4.1-8 (for 
CART). 
4.3 RESULTS 
4.3.1 Study populati(}n 
5729 children with fever of less than 72 hours were enrolled at one of the seven clinical 
study sites in southern Vietnam between October 2010 and December 2012. A summary of the 
patient screening, enrolment and diagnostic outcomes is shown in Supplementary Figure 4-1. A 
total of 5707 patients were inCluded in the analyses. 1692 (29.6%) participants had laboratory-
confirmed dengue. The baseline characteristics of the dengue and non-dengue cases are shown in 
Table 4-1. Notably, dengue cases were older than non-dengue cases. All four DENV serotypes 
were detected; DENV-l was the commonest serotype, followed by DENV-4, -2 and -3. 
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Table 4-1:.Baseline characteristics ofstudy participants 
Demographic characteristics 
Age (years) 
Sex-Male (n, %) 
BMI (kg/(m)2) 
History and clinical characteristics 
Day of illness 
1 
2 
3 
Temperature (cC) 
Vomiting (n, %) 
Abdominal pain (n, %) 
Skin bleeding (n, %) 
Mucosal bleeding (n, %) 
Flush (n, %) 
Hepatomegaly (n, %) 
Rash (n, %) 
Conjunctival injection (n, %) 
Laboratory results· 
WBC (103/mm 3) 
PLT (103/mm 3) 
HCT (%) 
ALB (glL) 
AST (U/I) 
CK (U/I) 
Laboratory-confirmed 
dengue 
(N=1692) 
9 (6-11) 
945 (55.9%) 
16.4 (14.6-18.9) 
361 (21.3%) 
692 (40.9%) 
639 (37.8%) 
38.5 (38-39) 
737 (43.6%) 
351 (20.7%) 
243 (14.4%) 
113 (6.7%) 
399 (23.6%) 
6 (0.4%) 
62 (3.7%) 
343 (20.3%) 
4.74 (3.50-6.80) 
180 (141-227) 
38.6 (36.6-40.7) 
43.7 (41.7-45.6) 
51 (40-67) 
105 (82-140) 
• All laboratory results were acquired on the day of enrolment. 
Non-Dengue 
(N=401S) 
5 (3-8) 
2249 (56.0%) 
15.6 (14.1-17.6) 
1232 (30.7%) 
1732 (43.1%) 
1051 (26.2%) 
38.4 (37.8-39.0) 
1442 (35.9%) 
702 (17.5%) 
135 (3.4%) 
99 (2.5%) 
532 (13.3%) 
5 (0.1%) 
79 (2.0%) 
385 (9.6%) 
8.90 (6.36-12.40) 
242 (200-292) 
37.4 (35.3-39.6) 
43.9 (42.0-45.7) 
42 (35-49) 
100 (76-131) 
Values are presented as median and interquartile range for continuous variables or 
frequency and percentage for categorical variables. 
BMI: body mass index; WBC: white blood cell count; PLT: platelet count; HCT: haematocrit; 
ALB: albumin; AST: aspartate aminotransferase; CK: creatine kinase. 
4.3.2 Diagnostic accuracy of the NSI Ag Strip test and association with viraemia 
Enrolment plasma samples (n=5707) were tested for the presence ofNS 1 by NS 1 Ag Strip 
test in a blinded, real-time fashion. Against the composite gold-standard reference diagnostic result. 
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the NSl Ag Strip test had a sensitivity of 70.4% (95%CI: 68.2-72.6%), specificity of 99.2% 
(95%CI: 98.9-99.5%), positive predictive value (PPV) of 97.4% (95%CI: 96.3-98.2%), and 
negative predictive value (NPV) of 88.9% (95%CI: 87.9-89.8%) for the diagnosis of dengue 
(Table 4-2). There was a striking difference in diagnostic perfonnance by serotype, with NS 1 
detection being less sensitive in DENV-2 infections irrespective of the serological response 
(primary vs. secondary) (Supplementary Table 4-2). The detection ofNS 1 was strongly associated 
with the concentration of DENV RNA in the same plasma sample; the odds of NS 1 detection 
increased by 1.8 (95%CI: 1.6-1.9) for each 10-fold higher DENV RNA concentration (Table 4-2). 
These data define the strengths and weaknesses of NS 1 rapid testing; it is highly specific but is 
compromised by suboptimal sensitivity, especially for DENV -2 cases. 
Table 4-2. Diagnostic performance of NSl rapid test in enrolment plasma samples and 
odds of NSl detection in relation to plasma viraemia 
Laboratory- Non-dengue Total 
confirmed dengue Cases 
cases. 
NSl rapid test 1192 32 1224 PPV % = 97.4% 
positive (96.3-98.2%) 
NSl rapid test 500 3983 4483 NPV%=88.9% 
negative (87.9-89.8%) 
Total 1692 4015 5707 
Median (IQR) OR (95%CI) Sensitivity % Specificity % (95%CI) 
plasma viral RNA (95%CI) 
concentration 
(logl0copies/ml)' 
All serotypes 7.3 (6.2-8.3) 1.8 (1.6-1.9) 70.4% (68.2-72.6%) 99.2% (98.9-99.5%) 
(n=1692) 
DENV-l (n=629) 7.9 (6.6-8.7) 2.0 (1.8-2.3) 80.3 (77.0-83.3%) 
DENV-2 (n=399) 7.0 (6.0-7.9) 1.8 (1.5-2.1) 46.4 (41.4-51.4%) 
DENV-3 (n=154) 7.5 (6.4-8.6) 1.4 {1.1-1.9) 85.1 (78.4-90.3%) 
DENV-4 (n=433) 6.9 (6.0-7.7) 1.5 (1.3-1.8) 75.8 (71.3-79.7%) 
• Viraemia measurement in the same plasma sample was used for NSl testing. 
PPV: positive predictive value; NPV: negative predictive value; DENV: dengue virus; OR: odds ratios for 
detecting NSl for each 10-fold higher DENV RNA concentration. There were 77 dengue cases where the 
Infecting serotype was unknown. 
4.4 Manipulation of plasma specimens to improve NSl detection 
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Volume enrichment of the plasma molecular weight fraction containing multimeric NSl 
(> 1 OO,OOOkDa) was performed on plasma samples from 21 viraemic dengue cases enrolled in this 
study. However, despite 5-10-fold concentration of plasma, this processing failed to materially 
improve the diagnostic yield, with only 1 of 11 samples changing their status from negative 
(original sample) to positive (concentrated sample) in the Platelia NS 1 ELISA (Supplementary 
Table 4-3). 
4.5 Tile Early Dengue Classifier; a diagnostic rule based on clinical and simple laboratory 
features 
Multivariate logistic regression analyses of clinical, demographic and laboratory data from 
5707 patients were performed to generate a practical dengue diagnostic classifier that could replace 
or augment NSl-based diagnosis in the first 72 hours of illness. The most parsimonious model, 
derived from stability selection, used the patient's age, white cell count and platelet count at the 
time of enrolment to classify dengue from non-dengue cases (Table 4-3). Alternative approaches 
to feature selection yielded models with only slightly higher performance but relied on many more 
(more than ten) variables (Supplementary Table 4). The most parsimonious model, herein called 
the I;.arly Dengue hlassifier (EDC), had a sensitivity of 74.8% (95%CI: 73.0-76.8%), specificity 
of 76.3% (95%CI: 75.2-77.6%), positive predictive value of 57.1% (95%CI: 56.2-59.0%), and 
negative predictive value of 87.8% (95%CI: 86.8-88.5%) for correctly classifying dcngue cases in 
the entire dataset at the pre-defined cut-off of 33.3%. Of note, this pre-defincd cut-off reflecting 
clinical priorities was very close to the cut-off corresponding to the point on the ROC curve closest 
to the upper left corner (perfect modcl), which was 34.2% (Figure 4-1 A). The area under the ROC 
curve (AUC) ~as 0.829 (Figure 4-IB) and the predicted risk of dengue agreed well with the 
observed risk (Figure 4-1 C). The EDC had sensitivity of72.9% (95% Cl: 69.6-76.6%) for DENVI, 
74.7% (95%CI: 71.0-79.7%) for DENV2, 68.4% (95%CI: 59.2-74.5%) for DENV3 and 78.2% 
(95%CI: 75.5-83.3%) for DENV4 infection. The overall performance characteristics of the EDC 
under temporal, leave-one-site-out validation or seasonality (rainy versus dry season), are 
summarized in Supplementary Table 4-5. These results suggest that, in settings where NS 1 rapid 
tests are not routinely available, the EDC could assist primary care physicians in dengue diagnosis. 
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Table 4-3. Unh'ariate and mnltivariate analysis of candidate predictors of laboratory-confirmed dengue 
Univariate analysis Multivariate analysis 
Full model with all candidate predictors Final model based on stability selection 
OR 95%0 P OR 95%0 P OR 95%0 P 
Demographic: 
characteristics 
Age (by + 1 year) 1.24 1.22-1.26 <0.001 1.21 1.18-1.24 <0.001 1.15 1.13-1.17 <0.001 
Sex: Male 0.99 0.89-1.11 0.909 0.94 0.81-1.09 0.432 
BMI (by +1) 1.09 1.07-1.11 <0.001 1.06 1.04-1.09 <0.001 
History and clinical 
characteristics 
Day of illness (+1 day) 1.45 1.34-1.56 <0.001 0.78 0.70-0.87 <0.001 
Temperature (by +rq 1.23 1.14-1.32 <0.001 1.28 1.16-1.40 <0.001 
Vomiting:: Yes 1.37 1.22-1.54 <0.001 1.31 1.12-1.52 <0.001 
Abdominal pain:: Yes 1.24 1.07-1.42 0.004 0.91 0.76-1.10 0.349 
Skin bleeding:: Yes 4.82 3.87-5.99 <0.001 2.08 1.53-2.84 <0.001 
Mucosal bleeding = Yes 2.83 2.15-3.73 <0.001 1.02 0.67-1.53 0.934 
Flush =Yes 2.02 1.75-2.34 <0.001 1.37 1.11-1.69 0.003 
Hepatomegaly:: Yes 2.85 0.87-9.36 0.086 0.58 0.05-7.08 0.687 
Rash =Yes 2.02 1.75-2.34 <0.001 1.23 0.78-1.93 0.381 
Injection = Yes 2.40 2.05-2.81 <0.001 1.58 1.25-1.99 <0.001 
Laboratory results 
WBe (+101/mml) 0.70 0.68-0.71 <0.001 0.77 0.75-0.80 <0.001 0.78 0.76-0.80 <0.001 
PLT (+104/mml) 0.87 0.86-0.88 <0.001 0.97 0.95-0.98 <0.001 0.94 0.93-0.95 <0.001 
HCT (+1%) 1.12 1.10-1.14 <0.001 0.97 0.95-0.99 0.013 
AlB (+1g/1) 0.97 0.95-0.99 0.004 1.00 0.98-1.03 0.787 
AST (per 2-fold 3.65 3.23-4.14 <0.001 3.50 2.97-4.13 <0.001 
increase) 
eK (per 2-fold increase) 1.33 1.24-1.43 <0.001 0.84 0.76-0.93 <0.001 
BMI: body mass index; WBe: white blood cell count; PLT: platelet count; HCT: haematocrit; ALB: albumin; AST: aspartate aminotransferase; eK: creatine kinase 
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Final model for whole data. n=5707 
A .. r:--------;.,.-.----, 
...... Possible cutoff=O.342 ", 
Figure 4-1. Performance of the Early Dengue 
Classifier (EDC) in all subjects. Figure 4-1A displays 
possible sensilivity/specijicilY trade-offs for different 
cut-off values and the distance from the corresponding 
points on the ROC curve to the upper left corner (perfect 
model). Figure 4-1B displays the receiver operating 
characteristic (ROC) curve. Figure 4-1C is a calibration 
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In settings where NS 1 rapid tests are routinely used, the EDC can be combined with the 
NS 1 rapid test as a composite test (classified as positive when either NS 1 rapid test or EDC are 
positive, and classified as negative when both NSl rapid test and EDC are negative). This 
composite test had sensitivity of 91.6% (95%CI: 90.4-92.9%) while the specificity was 75.7% 
(95%CI: 74.5-77.0%). Corresponding positive and negative predictive values were 61.7% (95%CI: 
60.6-63.1 %) and 95.5% (95%CI: 94.9-96.1 %). If a higher specificity was desired, a higher cut-off 
value of the EDC could be used for the combined test instead, e.g. a cut-off of 50% would lead to 
a sensitivity of86.0% (95%CI: 84.5-87.6%) and specificity of89.6% (95%CI: 88.7-90.5%). These 
results imply that the EDC is useful in settings with and without NS 1 rapid testing. 
4.6 User-friendly applications of the Early Dengue Classifier 
Figure 4-2 presents a nomogram of the EDC. The nomogram assigns points to all risk 
factors and translates the total point score to a predicted risk for dengue. For example, a 9-year-
old patient with platelet count 100xI03/mm3, and white blood cell count 5x103/mm3 has a total 
points score of 15+32+84= 131, and the correspond ing risk of dengue is about 70%. The predicted 
risk of dengue is larger than 33.3% so the patient would be classified as dengue positive. 
Alternatively, the EDC could be implemented as a smartphone app. The exact formula for the 
estimated risk of dengue (p) is given by the following logistic equation: logit(p)=1.236 + 
0.139*age (in years) - 0.254*white blood cell (in 1 03/mm3) - 0.006 ·platelet (in 103/mm3). 
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Figure 4-2. Nomogram of the Early Dengue Classifier (EDC) to predict the risk of dengue. A 
horizontal line from a predictor value to the "Points" axis assigns points to the 3 required 
variables age, platelet count (PLT), and white blood cell count (WBC). The sum of these points 
(total points) can then be translated to the corresponding predicted risk of dengue. As an example, 
a 9-year-old patient with a PLT of JOOx1rYlmmJ, and a WBe of 5x1rYlmmJ has a score of 
15+32+84=131, and the corresponding risk of dengue is about 70%. Note: As <1% of patients 
had platelet (P LT) count> 500x1 rY ImmJ or white blood cell (WBC) count> 30x 1 rY ImmJ, for better 
visualization, PLTand WBe counts were truncated at 500xJOJlmmJ and 30x1rYlmmJ respectively. 
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4.7 DISCUSSION 
The early and accurate diagnosis of dengue on the grounds of clinical signs and symptoms 
alone is problematic [153]. Physicians need better tools to assist in early diagnosis if the WHO 
ambition of a 50% reduction in global dengue mortality is to be achieved by 2020. This study 
characterized the performance of three diagnostic approaches; the NS I rapid test, a stand-alone 
diagnostic classifier and the combination ofNS I rapid test and diagnostic classifier together. Our 
results highlight the utility ofNSI rapid tests for an early specific diagnosis, yet also remind that 
2nd generation tests are needed with improved sensitivity. The diagnostic classifier described here 
could help guide diagnosis in endemic settings, or be used as an adjunct to help exclude dengue in 
patients returning a negative NS I rapid test result. 
There is a body of literature describing the performance ofNS 1 rapid tests for the diagnosis 
of dengue [96, 98, 108, 113, 152, 161, 162]. This current study extends that literature in several 
ways. First, by virtue of the large sample size we demonstrate with high precision the differential 
sensitivity of the NSI Ag STRIP for different DENV serotypes. This test was sensitive (between 
75-85%) for DENV-I. -3 and -4 infections, but poorly sensitive in DENV-2 infections (46.4%). 
Lower sensitivity was partially attributable to the great majority of DENV-2 infections being 
associated with secondary serological responses, although we note sensitivity was also low in 
primary DENV-2 infections. This suggests that there are particular virological (e.g. lower viral 
burdens in vivo) or intrinsic aspects of the NS I test, that limit DENV -2 NS I detection. [92, 128, 
145, 163]. Second, we make the novel observation that 5-10 fold enrichment of proteins with 
molecular weight> I OOkDa in plasma specimens (the NS 1 hexamer has predicted molecular 
weight of3lOkDa [164]) did not lead to improved NSl detection rates. These data suggest that 
dengue patients who return negative NS 1 rapid test results in the first 3 days of illness have free 
plasma NS 1 concentrations substantially below the limit of sensitivity of existing assays and that 
2nd generation tests might need to be at least an order of magnitude more sensitive. Nonetheless, 
better NS 1 rapid diagnostic tests are needed if they are going to be widely adopted by clinical 
services in primary care settings. In malaria, HRP2 rapid diagnostic tests for Plasmodium 
/alciparum infection are an example of how improvements to assay performance can lead to 
recognition as a diagnostic standard of care [165]. Finally, although serum NSl concentrations 
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have been proposed to have prognostic value in a small study, this is yet to be independently 
validated and is likely to be difficult given that blood NS I concentrations vary widely according 
to the infecting DENV serotype, serological response and day of illness [98, 109, Ill, 128]. 
A body of literature describes clinical and/or routine laboratory findings that distinguish 
patients with dengue from those with other febrile illnesses [155, 166-172]. What is striking in the 
literature is that only three prospective studies have considered dengue diagnostic algorithms 
exclusively in children and of these the largest contained 1227 patients, of who 614 had dengue 
[32, 173, 174]. More generally, most diagnostic studies failed to report positive and negative 
predictive values for their diagnostic algorithms, thus making it difficult to assess their utility in 
routine practice. Against this backdrop, a strength ofthe current study is the large sample size, the 
presence of all four DENV serotypes, robust statistical validation techniques and transparent 
performance characteristics. The clinical signs and symptoms that make ~p the WHO case 
definition for dengue were not used in the final, parsimonious diagnostic EDC classifier. Instead, 
we found that only three variables- patient age, white blood cell count and platelet count, provided 
similar discriminatory information as alternative models that relied upon a much larger set of 
clinical data. 
The purpose of this study was to explore whether it was possible to develop any kind of 
simple, evidence-based algorithm for early diagnosis - the results demonstrate this feasibility, 
albeit the performance characteristics of the end-result algorithm are not so outstanding that they 
will result in widespread adoption. The sensitivity (74.8%), specificity (76.3%) and positive 
predictive value (57.1%) of the EDC were not outstandingly high and as such will not change the 
practice of experienced clinicians. We concur with Potts et 01 in the belief that diagnostic rules 
for dengue are not a replacement for good clinical acumen and management [153]. However, the 
EDC described here offers an evidence-based guide that can likely improve the prevailing 
diagnostic accuracy of most Vietnamese physicians working in primary care who do not possess 
extensive experience in dengue diagnosis and management. In particular, in settings where NS 1 
rapid tests are not routinely available or affordable, or where DENV -2 is the most prevalent virus 
in circulation, the EDC could help guide clinicians in making their differential diagnosis. An early 
diagnosis of dengue can assist in patient triage and management by directing c1inicaVcaregiver 
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attention to clinical warning signs and/or the appearance of capillary permeability, for which 
supportive oral and/or parenteral fluid therapy is recommended in order to prevent circulatory 
compromise. Additionally, in the first days of illness many dengue cases are infectious to Aedes 
aegypli mosquitoes and hence an early diagnosis could support measures to prevent further 
transmission, e.g. by use of topical repellents and local mosquito control [138]. 
Our study has several design features and limitations that might preclude its wider 
generalizability. The Eoe relies on routine haematology findings that are commonly accessible in 
primary care settings in Vietnam but might not be available everywhere. By design, our study 
focused on patients with <72 hours of illness and hence our results might not be applicable to 
patients who present to medical care at later time-points. By using the age of the patient as a 
component of the EOe, it's likely that the EOe would not perform well in settings where the 
burden of dengue falls on age-groups different from that in southern Vietnam. Nonetheless, this 
study has delivered the largest population-based and quantitative framework to guide early 
diagnosis of paediatric dengue. Further prospective validation in Vietnam and other endemic 
countries with similar epidemiology will be needed to establish the clinical utility of the EOe. 
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APPENDIX 
I 6017 Patients were assessed for eligibility I H 288 Old not meet the 
Inclusion/exclusion alterla 
I 5729 Patients enrolled I 
~ 2 Were recruited twite 1 Withdrawn by parent 
I 5726 Had demographic and clinical data available I 
~ 2 Had haematological test errors J 
I 5724 Had demographic, clinical and haematological data available J H 14 Had missing values for biochemistry 
and J had biochemistry test errors 
I 5707 Had complete demographic, haematologlcaland biochemical results available I 
.J, 
1-
.J, 
[1692 Were laboratory-confirmed dengue cases' 4015 Were non-dengue I 
-r 
.J, 
.J, .J, .J, 
--t 
RT-PCR positive RT-PCR negative and RT·PCR negative, RT-peR negative, RT·peR negative and 
n=1611 NS1 Platella positive NS1 Platella negative N51 Platella negative and N 51 Platella negative 
. 
n=65 and IgM seroconverslon no IgM seroconverslon (presumptive not·dengue) 
n=16 (not dengue) n=3372 
n=643 
Supplementary Figure 4-1. Flow chart showing patient enrolment and classification. 
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Supplementary Figure 4-2. Plots of estimated component smooth functions of a GAM for the 
risk of dengue which included all candidate predictors listed in Supplementary Table 4-1 and 
modelled continuous parameters as smooth terms. Only terms estimated to have a non-linear 
association with outcome are displayed. Dots correspond to individual partial residuals; solid lines 
correspond to smooth spline functions estimated by GAM; dashed lines correspond to the 
estimated smooth functions plus/minus one standard error. 
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Supplementary Table 4-1. Clinical and demographic features recorded at the time ohtudy 
enrolment 
Variable 
1. Day of illness (days) 
2. Age (years) 
3. Sex 
4. BMI (kg/(m)2) 
5. Temperature at enrolment eC) 
6. Vomiting (YeslNo) 
7. Skin bleeding (YeslNo) 
8. Mucosal bleeding (YeslNo) 
9. Abdominal pain (YeslNo) 
10. Rash (YeslNo) 
11. Flush (YeslNo) 
Definition 
Day of illness at enrolment 
Age in years 
MalelFemale 
Body mass index (BMI) = weight (kg) /height (m) "2 
Axillary temperature at enrolment 
Any episode of vomiting in history of illness 
History or clinical examination shows that the patient has 
skin bleeding, e.g. petechiae or ecchymosis. 
Any frank bleeding from any mucosal site e.g. epistaxis, 
gingival bleeding, gastrointestinal bleeding, or urogenital 
bleeding in history of illness or medical examination 
History or clinical examination shows that the patient has a 
painful feeling at the abdomen by self-reporting or elicited on 
gentle palpation. 
. Clinical examination reveals generalised macular, blanching, 
non-petechial rash. 
Redness of the skin caused by dilatation and congestion of the 
capillaries that blanches with pressure. 
12. Conjunctival injection (YeslNo) Redness (bright red or pink) of the conjunctiva fading 
towards the limbus due to dilatation of the superficial 
conjunctival blood vessels. 
13. WEC (I03/mm3) 
14. HCT(%) 
15. Platelet count (I03/mm3) 
16. ALB (gIL) 
17. AST (UIl) 
18. CK (UII) 
Absolute white blood cell count at enrolment 
Haematocrit at enrolment 
Platelet count at enrolment 
Blood albumin concentrations 
Blood aspartate aminotransferase concentrations (Iog2-
. transformed) 
Blood creatine kinase concentrations (log2-transformed) 
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Supplementary Table 4-2. Sensitivity ofNSI rapid test according to serotype and 
serological response in hospitalized patients 
DENV-l 
DENV-2 
DENV-3 
DENV-4 
Unknown 
Total 
Sensitivity % (95%CI) 
Primary infection 
(NS 1 + Itotal primary infection)a 
93.6% (87.2-97.4%) 
(107/109) 
42.9% (17.8-71.1 %) 
(6/14) 
95.2% (76.1-99.2%) 
(20/21) 
70.0% (45.7-88.0%) 
(14120) 
68.8% (41.4-88.9%) 
(11/16) 
180 
Secondary infection 
(NS 1 + Itotal secondary infection)b 
82.2% (75.5-87.8%) 
(134/163) 
57.1% (48.9-64.9%) 
(89/156) 
81.1% (64.8-92.0%) 
(30/37) 
81.1% (74.8-86.4%) 
(154/190) 
55.5% (30.8-78.4%) 
(10/18) 
564 
Note: (a), (b) indicated the number of cases with NSl rapid test positive compared to the total 
number o/primary or secondary injections respectively within the same individual dengue 
serotypes. 
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Supplementary Table 4-3. Detection ofNSl in viraemic blood samples collected at the time 
of enrolment, before and after volume concentration 
NSl status (Platelia EUSA)· 
loglO 
viraemia NSl Fold 
DENV RNA rapid Original Sample Sample concentration 
Sample# Serotype coples/ml test sample concentrate filtrate of sample 
15-222 2 6.85 + + 8.0 
16-427 2 6.90 + + 6.7 
16-134 1 9.54 + + + 6.7 
16-139 1 6.93 + + + 6.7 
16-142 1 8.22 + + + 8.0 
16-130 1 8.34 + + 6.7 
1-920 1 8.33 + + + 8.0 
16-184 1 7.95 + + 8.0 
16-223 2 6.33 + + 10.0 
16-269 1 5.40 6.7 
16-281 2 4.98 6.7 
16-308 1 5.19 5.7 
16-352 2 5.39 + 5.7 
16-399 2 4.49 4.0 
15-226 2 8.47 5.7 
16-155 1 3.11 5.7 
16-160 1 7.56 5.7 
16-514 1 7.36 Eq Eq 5.7 
16-154 1 2.94 6.7 
1-846 2 5.78 5.7 
1-882 1 11.05 8.0 
• NS1 Platelia test result: "+"=positive, "-"=negative, #lEq'= equivocal 
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Supplementary Table 4-4. Performance of models for the risk of dengue in all subjects resulting from different statistical 
modelling approaches 
Full model Step-wise Ale STAB CART RF 
Calibration intercept -0.414 (-O.47(H).554) -0.432 (-O.47(H).557) -0.200 (-O.81(H).852) -0.211 (-O.667~.833) -0.256 (-0.601-0.742) 
Calibration slope 0.926 (0.820-1.248) 0.920 (0.820-1.263) 1.075 (0.855-1.272) 1.076 (0.829-1.076) 1.293 (1.037-1.331) 
AUC 0.855 (0.815-0.861) 0.854 (0.815-0.861) 0.835 (0.792-0.850) 0.774 (0.703-0.777) 0.872 (0.83(H).873) 
Sensitivity (cutoff 0.33) 0.785 (0.651-0.868) 0.790 (0.659-0.890) 0.795 (0.659-0.912) 0.614 (0.459-0.736) 0.812 (0.579-0.846) 
Specificity (cutoff 0.33) 0.760 (0.699-0.868) 0.756 (0.699-0.868) 0.726 (0.55(H).839) 0.896 (0.735-0.939) 0.809 (0.709-0.873) 
PPV (cutoff 0.33) 0.535 (0.513-0.699) 0.533 (0.519-0.720) 0.505 (0.426-0.738) 0.676 (0.504-0.848) 0.600 (0.513-0.768) 
NPV (cutoff 0.33) 0.909 (0.815-0.936) 0.911 (0.811-0.946) 0.909 (0.748-0.945) 0.868 (0.702-0.884) 0.924 (0.805-0.926) 
The full model included all variables listed in Supplementary Table 4-1 plus interaction terms between age and WBC and between age and PLT. 
Step-wise AIC selected the fol\o~ing variables: age, day of illness, BM I, vomiting, temperature, skin bleeding, flush, injection, haematocrit, log2(aspartate ami 
notransferase), log2(creatine kinase), white blood cell count, platelet count, age by white blood cell count and age by platelet count. 
STAB selected the following variables from the full model: age, white blood cell count, platelet count. 
CART selected the following variables: age, white blood cell count. 
RF was derived from all variables listed in Supplementary Table 4-1. 
AUC: area under the ROC curve, PPV: positive predictive value, NPV: negative predictive value, Step-wise AIC: step-wise backwards variable selection using 
Akaike information criterion, STAB: stability selection, CART: classification and regression trees, RF: random forests. 
The results were from leave-one-site-out validation and were presented by mean and rangeo[performances across left out sites. 
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Supplementary Table 4-5. Performance of the Early Dengue Classifier (EDC) 
All patients 
Temporal Leave-one-site-out 
Dry season Wet season 
validation validation 
Calibration intercept 0 0 0 -0.247 -0.200 
(-0.810-0.852) 
Calibration slope 1 1 1 0.940 1.075 
(0.855-1.272) 
AUC 0.829 0.831 0.825 0.776 0.835 
(0.792-0.850) 
Sensitivity (cutoff 0.33) 0.748 0.731 0.783 0.786 0.795 
(0.730-0.768) (0.726-0.750) (0.771-0.798) (0.770-0.812) (0.659-0.912) 
Specificity (cutoff 0.33) 0.763 0.792 0.758 0.595 0.726 
(0.752-0.776) (0.781-0.803) (0.742-0.771) (0.583-0.612) (0.550-0.839) 
PPV (cutoff 0.33) 0.571 0.587 0.570 0.460 0.505 
(0.562-0.590) (0.579-0.602) (0.561-0.586) (0.451-0.482) (0.426-0.738) 
NPV (cutoff 0.33) 0.878 0.911 0.864 0.863 0.909 
(0.86H.885) (0.889-0.925) (0.851-0.972) (0.850-0.877) (0.748-{).945) 
Table shows apparent performance (95%CI) in all patients and seasons; performance (95%CI) in the validation set for temporal validation; and mean 
(range) of performances across left out sites for leave-one-site-out validation. Dry season is January to June, and wet season is July to December. 
The proportion of true dengue cases in all patients, dry season and wet season was 29.6% (1692/5707), 21.1 % (405/1916) and 33.9% (1287/3791) 
respectively. 
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Statistical appendix 
Assessment of linearity 
A generalized additive model (GAM) with integrated smoothness estimation as 
implemented in the R package mgcv version 1.8-0 was used to assess potential non-linear effects 
of variables on the risk of dengue. The model included all candidate predictors listed in 
Supplementary Table 4-1, and modelled continuous parameters as smooth terms. 
The GAM chose non-linear associations for several parameters including age, white blood 
cell count, and platelct count (Supplementary Figure 4-2). While the estimated association of 
outcome with age and white blood cell count was not perfectly linear, it was monotone and 
reasonably close to a linear function. Hence, these variables were treated as linear terms. 
The estimated effect of platelet count on the risk of dengue in Supplementary Figure 4-2 
indicates a dccreasing risk of dengue for increasing platelet counts up to -300x I 03/mm3 but a slight 
increase in the risk of dengue for higher platelet counts. J lowever, the performance of the final 
model in which platelet count was modelled non-linearly with a linear spline function with one 
knot at 300x 103/mm3 was similar to the one in which platelet was included as a linear term 
(AUC=O.830 vs. AUC=O.829). In addition, it seemed unclear whether it could be 
physiopathologically plausible for dengue patients to have abnormally high platelet counts or 
whether this was just an artifact. Thus, we presented in the main paper the results of the models in 
which platelet count was treated as linear term. 
Assessment of interactions 
Potential interactions. between age, sex, study site and haematological and biochemical 
results were examined by likelihood ratio tests based on the full model with all variables from 
Supplementary Table 4-1. 
Interaction terms between age and white blood cell count (p<O.OO 1) and between age and 
platelet count (p=O.039) were significant and added to the full starting model. 
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Chapter 5 
EARLY PROGNOSIS OF SEVERE DENGUE 
Summary 
We developed a prognostic algorithm using both clinical and laboratory features including 
vomiting, platelet count, AST and NS 1 rapid status to make prediction of severe dengue. 
5.1 INTRODUCTION 
Despite progress in management and resuscitation in intensive care, dengue with severe 
complications is still a cause of childhood mortality in many Asian and Latin American countries. 
The case fatality rate for dengue has declined over the last two decades and is now less than 1% 
with adequate treatment [I] but can reach as high as 26% in severe dengue if treatment is 
inappropriate [175]. One of the "costs" of achieving a low case fatality rate is the burden to the 
health care system from a large number of dengue cases being admitted for hospitalization and 
close observation, rather than ambulatory care. 
It. is a great challenge for general physicians and even experienced infectious disease 
physicians to predict in the first few days of the illness which dengue patients will evolve to severe 
dengue. Typical symptoms and signs of complications generally only occur in the critical phase, 
from day 4 to 6 of the disease [I, 150, 176]. Thus, in many settings, physicians working in the 
outpatient or emergency department setting often take a conservative approach with a suspected 
dengue case and admit the patient for monitoring. This has important implications for allocation 
of scarce healthcare resources, patient triage, reduction of unnecessary hospitalization and costs to 
patients. Previous studies have developed different approaches to identify early prognostic factors 
of severe dengue by using logistic regression or classification and regression trees [155, 174, 177, 
178]. However, the results from these previous studies are generally not useful in settings with 
limited resources e.g. where RT-peR techniques and serology are not routinely available. 
Furthermore, the majority of these studies only paid attention to dengue haemorrhagic fever (DHF), 
a case group who are not necessarily clinically severe [1, 154, 179, 180]. Indeed, the rationale for 
the refinement of the WHO case classification in 2009 was to more appropriately and inclusively 
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classify the clinically severe dengue cases, including those with dengue shock syndrome, severe 
bleeding or organ failure [I]. Additionally, most earlier prognostic studies had the notable 
limitation of not presenting the positive and negative predictive values of the prognostic tool, or 
that the predictive tools were based on data from patients who had already been hospitalized [155, 
181-184]. 
Given the knowledge gap in the field, the aim of this study was to develop a practical, 
prognostic tool to enable the early identification of patients at high risk of severe dengue. 
5.2 MATERIALS AND METHODS 
All information about study design, patient enrolment,· data collection and variable 
definitions were presented in Chapter 2 (Materials and Methods). To develop the prognostic 
models for severe dengue, we used logistic regression procedures using predefined clinical, 
haemobiochemical features and virus-related variables, i.e. NS 1 rapid test status, viraemia and 
dengue serotypes. Akaike information criteria (AIC) and Bayesian information criteria (BIC) were 
used to downselect from the original full models to the most parsimonious model for practical 
clinical application. 
Model validation was examined by two approaches; 
a) "Leave-one-site-out cross-validation", i.e. repeatedly developing the algorithm on all but 
one study site and validation on the left-out study site 
b) Temporal validation with patients recruited before 15 June 2012 as the training set and 
patients recruited thereafter as the evaluation set [156]. 
The final logistic regression model was converted to a nomogram for ease of use in clinical 
practice. All analyses were performed with the statistical software R version R v3.1.1 (R 
foundation for statistical computing, Vienna, Austria). Significance was assigned at p < 0.05 for 
all parameters and was two-sided. 
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5.3 RESULTS 
5.3.1 Baseline characteristics of study participants 
During the study period from Oct 2010 to Dec 2013, we enrolled 7563 patients with fever 
illness history of less than 72 hours at the outpatient departments of seven hospitals in southern 
Vietnam. A detailed description of the study profile is shown in Figure 5-1. The number of cases 
with complete haematological and biochemical data was 7544 patients, of whom 2060 (27.3%) 
had laboratory-confirmed dengue. DENV serotypes were identified by RT -PCR in 115/117 severe 
dengue patients (98.3%) and 1839/1943 non-severe dengue patients (94.6%). Table 5-1 describes 
the baseline characteristics of study patients. 
A range of clinical and laboratory features at the time of enrolment were associated with 
the development of severe dengue. In univariate analysis within the lab-confirmed dengue case 
population, a history of vomiting at the time of enrolment (OR=2.91 (95%CI: 1.96,4.33), p<O.OO I), 
abdominal pain (OR';"1.65 (95%CI: 1.09,2.49), p=0.018) and longer illness history (OR=1.53 per 
extra day of illness at enrolment (95%CI: 1.17, 1.99), p=0.002) were associated with development 
of severe dengue (Table 5-2). Furthermore, patients who developed severe dengue had 
significantly lower white blood cell (WBq count (OR per 1,000 cells/mm) increase =0.86 (95%CI: 
0.79, 0.93), p<O.OOI), lower platelet count (OR per 10,000 cells/mm3 increase =0.82 (95%CI: 
0.79,0.85), p<O.OOI) and lower albumin level (OR per Ig/L increase =0.92 (95%CI: 0.87,0.97), 
p=0.003) at the time of enrolment.. Additionally, a higher haematocrit (OR per 1 % higher Het 
=1.14 (95%CI: 1..08, 1.20), p<O.OOI), elevated aspartate aminotransferase (AST) (OR per two-fold 
higher =3.74 (95%CI: 3.00, 4.68), p<O.OOI), NSI positivity (OR=2.04, (95%CI: 1.25, 3.35), 
p=0.004) and higher viraemia concentrations (OR per 1 10gl0 RNA copies/ml higher =1.22 
(95%CI: 1.07, 1.39), p=0.003) were also associated with patients who subsequently developed 
severe dengue (Table 5-2). These data identify objectively early clinical and laboratory signs and 
symptoms associated with cases that will develop severe dengue from those with an uncomplicated 
outcome. 
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7563 patients enrolled 
19 Patients were excluded: 
- 2 Had missing values for haematology. 
- 17 Had missing values for biochemistry. 
7544 Patients had 
complete haematological 
and biochemical results 
available 
... 
5484 Patients were excluded because of 
being not dengue 
2060 laboratory-confirmed 
dengue 
106 Patients were excluded because of 
unknown serotype and peR results: 
- 2 severe dengue 
- 7 dengue with i.v. fluids 
1954 RT-PCR positive cases - 97 uncomplicated dengue 
had complete information 
for data analysis 
115 severe dengue 
1839 dengue 
Figure 5-1. Flow diagram of the analysis for the development of severe dengue 
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Table 5-1. Baseline characteristics ofstudy participants 
Severe dengue Non-severe dengue OFI 
(N=117) (N=1943) (N=5484) 
n Descriptive statistics n Descriptive statistics n Descriptive statistics 
Age (years) 117 9 (7-11) 1943 9 (6-11) 5484 5 (3-8) 
BMI (kgl(m)2) 117 16.9 (14.6-20.1) 1943 16.5 (14.7-19.0) 5484 15.6 (14.2-17.7) 
Day of illness 117 1943 5484 
I 15 (12.8) 1943 426 (22.0) 5484 1659 (30.3) 
2 43 (36.8) 1943 789 (40.8) 5484 2372 (43.4) 
3 59 (50.4) 1943 718 (37.1) 5484 1437 (26.3) 
Vomiting (n, %) 117 79 (67.5) 1943 804 (41.6) 5484 1902 (34.8) 
Abdominal pain (n, %) 117 . 34 (29.1) 1943 385 (19.9) 5484 930 (17.0) 
Mucosal bleeding (n, %) 117 9 (7.7) 1943 112 (5.8) 5484 134 (2.5) 
WBC (1 Ol/mml) 117 3.7 (2.5-5.8) 1943 4.9 (3.6-6.9) 5484 9.0 (6.4-12.5) 
PLT(101/mm3) 117 110 (86.5-147) 1943 182 (144-227) 5484 242 (201-291) 
HCT(%) 117 40 (37.8-42.3) 1943 38.6 (36.6-40.6) 5484 37.4 (35.3-39.7) 
ALB(gIL) 117 43.3 (40.5-45.1) 1943 43.8 (41.8-45.8) 5484 44.2 (42.2-46.2) 
AST(U/I) 117 101 (61.5-155) 1943 50 (40-66) 5484 42 (35-49) 
NSl rapid test '+' (n. %) 117 97 (82.9) 1943 1360 (70.4) 5484 37 (0.7) 
Viraemia concentration (log 1 Ocopieslml) 115 7.5 (6.4-8.3) 1839 7.2 (6.0-8.2) 
Serotype 115 1839 
DENV-l 38 (32.5) 725 (37.5) 
DENV-2 37 (31.6) 404 (20.9) 
DENV-3 6(5.1) 181 (9.4) 
DENV-4 34 (29.1) 519 (26.8) 
Unknown 2 (1.7) 104 (5.4) 
All laboratory results were acquired on the day of enrolment. 
Values are presented as median and interquartile range for continuous variables or frequency and percentage for categorical variables. 
BMI: body mass index; WBC: white blood cell count; PL T: platelet count; HCT: haematocrit; ALB: albumin; AST: aspartate aminotransferase, 
OFI: other febrile illness. 
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Table 5-2. Univariate analysis of candidate predictors of severe dengue 
Severe dengue vs. Non-severe dengue 
OR 95%CI P 
Age (+ 1 year) l.00 0.95, 1.06 0.920 
BMI (+ 1 kg/(m)2) 1.03 0.98, 1.09 0.223 
Day of illness (+ 1 day) 1.53 1.17, 1.99 0.002 
Vomiting: Yes 2.91 1.96,4.33 <0.001 
Abdominal pain: Yes 1.65 1.09.2.49 0.018 
Mucosal bleeding: Yes 1.35 0.67,2.73 0.405 
WBC (+1,000 cells/mm3) 0.86 0.79,0.93 <0.001 
PLT(+IO,OOO cells/mm3) 0.82 0.79,0.85 <0.001 
HCT(+ I %) 1.14 1.08,1.20 <0.001 
ALB (+ I gIL) 0.92 0.87,0.97 0.003 
AST (per 2-fold increase) 3.74 3.00,4.68 <0.001 
NS 1 rapid test status '+': Yes 2.04 1.25,3.35 0.004 
Viraemia: (+llogIOcopies/ml) 1.22 1.07, 1.39 0.003 
Serotype • 
DENV-I 1.00 
DENV-2 1.74 1.09,2.79 0.020 
DENV-3 0.63 0.26, 1.52 0.305 
DENV-4 1.25 0.78,2.02 0.355 
BMI: body mass index; WBC: white blood cell count; PLT: platelet count; HCT: haematocrit; ALB: albumin; AST: aspartate 
aminotransferase 
': Univariate effect of serotype on severe dengue estimated from univariate logistic regression, using DENY -I as reference 
group. 
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5.3.2 Prognostic models for early identification of severe dengue cases from amongst all true 
dengue cases 
We sought to determine whether a simple, clinically useful prognostic algorithm for severe 
dengue could be derived from the informative clinical and laboratory signs identified above. We 
used logistic regression analysis to examine the impact of predefined clinical, haemobiochemical 
features, NS 1 rapid test status, viraemia and dengue serotypes on severe dengue. For simplicity, 
all continuous variables were treated as linear terms in the multivariable model development of 
the prognostic algorithm (Supplementary Table 5-1, Supplementary Figure 5-1 and Statistical 
appendix). There was no interaction between age or day of illness and all other predictors. The 
most parsimonious prognostic model, herein called the ~arly ~evere Dengue Identifier (ESDI), 
included vomiting, platelet count, AST (per two-fold increase) and NS 1 rapid test status at the time. 
of enrolment (Table 5-3). Alternative approaches to feature selection yielded models with only 
slightly higher performance but relied on many more variables and/or viraemia concentration by 
RT-PCR which is usually not feasible in clinical practice (Supplementary Table 5-2). Figure 5-2 
and Table 5-4 illustrate the performance characteristics of the ESDI at various cut-offs in the 
population of confirmed dengue cases. At the cut-off of 0.05 the ESDI had a sensitivity of 77% 
(95%CI: 69-84%), specificity of71% (95%CI: 69-73%), positive predictive value of 14% (95%CI: 
12-17%), and negative predictive value of 98% (95%CI: 97-99%) for correctly discriminating 
severe dengue cases in the dengue population. The rationale for the electing a risk threshold of 
0.05 was that the "cost" of missing a true severe dengue case as 20 times higher than the cost of a 
false-positive [157]. Note, this predefined cut-off, based on clinical priorities, was very close to 
the point on the ROC curve closest to the upper left corner (perfect model), which was 0.048 
(Figure 5-2A). The area under the ROC curve (AUC) of the ESDI amongst the population of true 
dengue cases was 0.83 using the cut-off of 0.05 (Figure 5-2B). 
The calibration plot shows that the ESDI overestimates the risk of severe dengue in the 
highest decile of predicted probability (Figure 5-2C), i.e. patients scored as having the highest 
decile of risk actually have a lower true risk than the model suggests (Figure 5-3 and Table 5-4). 
A summary of the performance characteristics of the ESDI by temporal and leave-one-site out 
validation is presented in Table 5-5. The ESDI clearly showed good discriminative performance 
for both temporal and leave-one-site out validation with an AUC of at least 0.89. 
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Table 5-3. Multivariate analysis of candidate predictors for severe dengue amongst RT -peR positive dengue cases 
Full model with predefined Reduced model by step-wise Alternative model 
candidate predictors BIC (ESDI) 
OR 95%CI p OR 95%CI P OR 95%CI p 
Age (+ 1 year) 0.94 0.87, 1.01 0.109 
BMI (+ 1 kgl(mf) 1.02 0.96,1.09 0.547 
Dayofillness (+ 1 day) 1.69 0.58,1.18 0.295 
Vomiting: Yes 1.82 1.15,2.88 0.011 1.86 1.21,2.87 0.005 2.00 1.30,3.07 0.002 
Abdominal pain: Yes 0.95 0.57, 1.58 0.847 
Mucosal bleeding: Yes 1.37 0.61,3.09 0.451 
WBC (+ 1,000 cells/mm) 1.07 0.96, 1.19 0.227 
PLT (+1 0,000 cells/mm3) 0.85 0.80,0.89 . <0.001 0.86 0.83,0.90 <0.001 0.87 0.84,0.91 <0.001 
HCT(+ 1 %) 1.07 LOO, 1.14 0.061 
ALB (+ 1 gIL) 0.98 0.92,1.06 0.655 
AST (per 2-fold increase) 2.70 2.06,3.53 <0.001 2.70 2.09,3.48 <0.001 2.64 2.04,3.40 <0.001 
NSl rapid test '+': Yes 2.46 1.30,4.66 0.006 2.63 1.52,4.57 <0.001 
Viraemia: (+llogIOcopieslml) 1.42 1.18, 1.70 <0.001 1.44 1.23,1.69 <0.001 
Serotype 
DENY-l 1.00 
DENY-2 2.18 1.25,3.82 0.006 
DENY-3 0.69 0.27, 1.76 0.434 
DENV-4 1.61 0.92,2.81 0.096 
Full model with predefined candidate predictors: clinical, haemobiochemical features, NS 1 rapid test status, viraemia concentration, 
serotype. 
Alternative model included only 4 variables: vomiting, platelet count, AST (per 2-fold increase), NS I rapid test status. 
WBC: white blOod cell count; PLT: platelet count; HCT: haematocrit; ALB: albumin; AST: aspartate aminotransferase; ESDI: 
Early Severe Dengue Identifier 
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A Final model for dengue population, n=1954 
,CUloll=O.Q4.8 ••••••••••••••• 
\ ..... . 
, 
, 
... 
... 
... 
...... 
Sensilivi1y 
Spe",ficily 
D,stance 
o ~----~------... r-~-------~-~-~-~-~.r 
B 
0.0 0.25 0.5 
Cutoff 
0.75 
Final model for dengue population, n=1954 
~r---------~======~ 
co 
~ 0 i: 
~ 0 
.. N 
d 
o 
AUC" 0.83 
o ~ ____ ~ __ ~ ____ ~ __ ~~ __ ~ 
0.0 0.2 0.4 0.6 0.8 1.0 
False POSItive rate 
C Final model for dengue population, n"1954 
t~ 1,0 •••• Slope 1.00 •••• 0.8 C (ROC) 0.83 •••••• . ' ~ 0.6 ~":'::': ••••• 
-8 •• • ~~~r" • 
~ 0.4 •• .l:.:;.... ___ Ideal 
? 0 2 .N'... . .. Nonparamelrie :x . .,.. .. Grouped pa~8nls 
J 
~-r#' 
0.0 .... .,..11_" __ --, ____ -.-___ s..,"vr-
ere 
__ 
de
_"9..,U<lr-+ ___ ,..J S8vere dengue· 
0.0 0.2 0.4 0.6 0.8 1.0 
Predicted severe dengue probability 
Figure 5-2. Performance of the Early Severe 
Dengue Identifier in RT -peR positive dengue 
patients. Figure S-2A displays possible 
sensitivity/specificity trade-offs for different cut-
off values and the distance from the corresponding 
points on the ROC cun'e to the upper left 
corner (perfect model). Figure S-2B displays the 
receiver operating characteristic (ROC) curve. 
Figure S-2C is a calibration plot. It displays a 
scatter plot-smoother of predicted versus observed 
risks (dotted line), predicted versus observed risks 
for ten patient strata of equal size grouped 
according to predicted risks (triangles) and the 
ideal identity line (dashed line). The rugs at the 
bottom of the graphs characterize the distribution 
of predicted risks in severe dengue and non-severe 
dengue cases, respectively. 
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Table 5-4. Number of true positive and false positive severe dengue cases according to 
different cut-offs for classification 
Risk thresholds Number of true positives N umber of false positives 
I 
0.000 115 1839 
0.005 114 1603 
0.010 111 1370 
0.050 89 526 
0.100 71 223 
0.200 48 72 
0.300 37 32 
0.400 28 16 
0.500 11 8 
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Figure 5-3. Changes in number of true and false positive severe dengue cases according to 
different cut-offs for classification when the ESDI is applied on the whole data. 
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Table 5-5. Performance of the Early Severe Dengue Identifier (ESDI) 
All RT- All study Temporal Leave-one-site-
peR participants validation out validation 
positive 
patients 
Calibration intercept 0 0.06 0.18 0.51 
(-0.09 - 0.69) 
Calibration slope 1.12 1.63 1.35 
(0.81 - 1.39) 
AUC 0.83 0.95 0.90 0.89 
(95%CI) (0.79, 0.87) (0.92,0.98) (0.76,0.87) (0.78 - 0.92) 
Sensitivity (cutolT 0.05) 0.77 0.87 0.91 0.88 
(95%CI) (0.69,0.84) (0.80, 0.92) (0.85-0.96) (0.68 - 0.93) 
Specificity (cutoIT0.05) 0.71 0.88 0.73 0.76 
(95%CI) (0.69,0.73) (0.87, 0.89) (0.70--0.75) (0.73-0.82) 
PPV (cutoIT0.05) 0.14 0.10 0.18 0.14 
(95%CI) (0.12, 0.17) (0.09, 0.12) (0.16-0.20) (0.13-0.23) 
NPV (cutoIT0.05) 0.98 0.998 0.99 0.98 
(95%CI) (0.97,0.99) (0.996,0.999) (0.98-0.99) (0.97-0.99) 
The prognostic model for severe dengue amongst RT-PCR positive dengue patients was the reduced 
modcl by step-wise mc, derived from the original full model which includcd all pre-delincd 
clinical, haemobiochemical features, NS 1 rapid test status, viraemia concentration and serotype. The 
table shows apparent performance (95%CI) in all dcngue patients; performance (95%CI) in the 
validation sct for temporal validation; and mean (runge) of performances across Icft out sites for 
Icave-one-sitc-out validation. 
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5.3.3 Performance oftbe ESDI amongst all enrolled cases (dengue and non-dengue) 
The ESDI had better performance when applied to the whole study population, (using the 
cut-off of~ 0.05) with an AUC of 0.95, sensitivity of 87% (95%CI: 80-92%), specificity of 88% 
(95%CI: 87-89%), positive predictive value of 10% (95%CI: 9-12%), and negative predictive 
value of99.8% (95%CI: 99.6-99.9%) for the prognosis of severe dengue (Table 5-5). 
5.3.4 A practical tool for pbysicians to predict severe dengue 
A nomogram was developed to predict severe dengue using the 4 independent parameters in the 
ESDI (Figure 5-4). The nomogram is used by totating the points assigned on the scales for each 
independent parameters. This total point is subsequently identified on the total points scale to 
achieve the risk of severe dengue. For example, a patient with vomiting, a PLT of 50,000/mm3, 
positive NS 1 rapid test and an AST of 240UIL (6-fold increase compared to the upper normal 
value of 40U/L) has a score of 8+92+ 12+30=142, and the corresponding risk of severe dengue is 
-30%. 
Points o . 10 , 20 . 30 . 40 , 50 , 60 . 70 , 80 , 
PLT (x 10'/mm') , • • • • • • • • • , 600 550 500 450 400 350 300 250 200 150 100 
n xASTupper 
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Figure 5-4. Nomogram oftbe prognostic model to predict tbe risk ofsevere dengue. A vertical 
line from a predictor value to the "Points" axis assigns points to the 4 required variables: vomiting, 
platelet count (PLT), NSl rapid test status and AST. The sum a/these points (total points) can then 
be translated to the corresponding predicted risk of severe dengue. As an example, a patient with 
vomiting, a PLTof 50xlrYlmmJ, positive NSJ rapid test and an AST of6times higher compared 
to the upper normal limit has a score of 8+ 92+ 12+ 30= 142, and the corresponding risk of severe 
dengue is about 30%. 
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5.4 DISCUSSION 
The great majority of clinically severe complications in paediatric dengue patients occur between 
the 4th and 6th day of illness [1, 150, 176]. Thus there is a window of opportunity in the first few 
days of illness to both make a diagnosis and try to predict which patients are at greatest risk of 
severe complications well before their onset. Yet the current standard of care in relation to 
prognosis relies on random clinical judgment. 
Here we demonstrate the feasibility of early diagnosis and prognosis «72 hours after illness onset) 
of severe dengue using simple clinical and laboratory investigations that are available in many 
endemic settings. A parsimonious scoring system, the ESDI, provides a simple tool for prognostic 
classification. The results will be particularly helpful in two scenarios. First, the ESDI might enable 
physicians to improve triage and clinical management (e.g. through more careful and frequent 
observations) of dengue cases in the outpatient setting- potentially resulting in fewer cases 
developing life-threatening severe outcomes. Second, the ESDI can assist clinical research studies 
aiming to enrol cohorts of patients who will develop severe disease at a higher frequency than 
would occur if simple consecutive enrolment of cases occurred, as is currently the standard 
approach in therapeutic trials [185-187]. Thus the ESDI could deliver efficiencies to clinical trials, 
i.e. cohorts enriched for severe clinical events that are not possible with the current standard of 
care. 
The ability to make an early, evidence-based prognosis of severe dengue could have practical 
rewards to clinical care, health systems and clinical research. First, the ESDI could assist clinical 
services in identifying at risk patients for triage to more regular observations than would occur 
under the current standard of care; this could mean hospitalization or more regular visits in an 
outpatient setting. Additionally, for outpatient care, communication to the patient's caregivers 
could be appropriately calibrated and with attention to WHO-nominated clinical warning signs [1]. 
The benefits of early prognosis, with accompanying closer clinical management, could potentially 
include a reduction in the frequency with which cases progress to severe disease and hence cost to 
the health care system and to families. However, the generally low positive predictive value of the 
ESDI (10% at a cut-off of 0.05) inevitably means that a large number of cases identified as being 
at risk of severe disease will in fact have uneventful disease evolutions. Nonetheless we believe 
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the ESDI delivers a useful tool to clinicians because they currently work in a vacuum of evidence 
with respect to predicting outcome in paediatric dengue cases with <72 hours of fever. 
NS I rapid tests are used as screening tools in trials of candidate dengue therapeutics [185-187]. 
By themselves these tests are helpful for early and rapid diagnosis, but it does not greatly assist 
the task of enriching clinical intervention studies with patients at greater risk of severe dengue. As 
an example, a clinical trial of early prednisolone therapy in 225 Vietnamese children observed that 
only 6.7% developed DSS in the placebo arm. Treatment trials in adult dengue cases observe an 
even lower incidence of severe dengue [185, 187, 188]. Thus, early phase treatment studies 
endeavouring to use severe dengue as a primary endpoint require large sample sizes to meet their 
objectives. The ESDI could enable efficiencies in trial performance by enriching the popUlation of 
participants with cases at higher risk of developing severe dengue. 
Most, but not all, of the parameters used in the ESDI are routinely collectable in primary care 
settings in Vietnam and other endemic countries. For example, the NS 1 antigen rapid test is 
available in most hospital emergency department'outpatient settings in Vietnam. NS 1 rapid tests 
are recommended by WIlD as a routine screening test for patients with clinically suspected dengue 
in the acute febrile phase [189] and are becoming more widely used in Vietnam. The diagnostic 
performance, and limitations, of this test has been extensively described in this patient cohort [190] 
and elsewhere [96, 98, 107, 113, 114, 116, 145, 163]. Previous studies also demonstrated that 
viraemia levels were strongly correlated with NSl rapid test status [63, 98, 109, 128, 191]. 
Ilaematology (platelet counts) and biochemistry (ASn were also important to the operation of the 
ESDI. Ilowever biochemistry is not routinely performed in outpatient settings and thus this 
represents an unmet need with respect to the operation of the ESDI. Potts et al previously observed 
that elevated AST in the first three days of illness was a predictor for severe dengue [178]. 
Presumably, early elevations in blood AST concentrations are a signal of the severity of 
disseminated virus infection and tissue damage. Some of the WHO-nominated warning signs of 
severe dengue, e.g. mucosal haemorrhage, clinical fluid accumulation and hepatomegaly were not 
prominent at the time of enrolment. This is not surprising since clinical experience indicates these 
are more likely to be present nearer to the time of severe complications occurring, i.e. day 4-6. 
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Not all DENV serotypes were equally associated with severe outcomes. DENV -2 in particular was 
over-represented amongst severe cases, consistent with previous studies [110, 122]. For reasons 
of study design, we could not dissociate whether DENV-2 was simply a proxy for secondary 
infection, itself a well-recognised risk factor for severe dengue, or was independently associated 
with severe dengue. We believe the former is more likely, since previous studies in this setting 
indicate that primary DENV-2 infections are rarely detected amongst hospitalized patients. 
Only one previous prospective study, of 1384 febrile Thai children (including 37 with DSS). by 
Potts et ai, is similar in study design to that reported here. Potts et al used classification and 
regression tree analysis to derive an algorithm from laboratory variables collected at the time of 
enrolment (platelet count, white blood cell count, monocyte percentage and haematocrit). The best 
algorithm had 97% sensitivity and 48% specificity for ihe identification of patients who progressed 
to DSS [178], however positive and negative predictive values were not reported. The study 
described here includes several important points of difference including-a) a much larger sample 
size and inclusion of clinically severe cases who did not have DSS, b) acquisition of clinical and 
laboratory data and c) validation of model performance. 
Our study, and the resulting ESDI, has some inherent limitations. First, the ESDI will not be 
suitable in all outpatient settings because NS I rapid tests and biochemistry are not always available. 
The ESDI is only applicable to observations made in the first 72 hours of illness; it's uncertain 
what the test performance will be o~tside this window of presentation. The evolution of dengue is 
probably impacted by clinical management; hence the incidence rate of severe dengue described 
in this study is likely to be context dependent; for the same patient population other settings might 
observe a lower or higher incidence of severe dengue and this could impact the prognostic 
classifier. Finally, though the ESDI has a good discriminative ability (AUC=O.83), the low PPV 
(common to many algorithms seeking to classify relatively rare events) means that the number of 
true severe dengue cases will be overestimated. Application of the ESDI may result in excessive 
hospitalizations, unnecessary follow-up procedures and the associated economic burden than 
would occur under the current standard of care. Further "pilot phase" research is needed to 
understand the benefits and disadvantages of the ESDI in routine practice and clinical research. 
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APPENDIX 
Supplementary Table 5-1. Linearity tcsts and interaction tests in tbe muItivariable logistic 
regression model for tbe development ofsevere dengue (based on the original full model 
including all pre-detined clinical, haemobiochemical features, NS 1 rapid test status, viraemia 
and serotype) 
Non-linear transformation Deviance df p value 
Linearity tests 
Age Restricted cubic spline with 4 knots 7.97 3 0.05 
BMI Restricted cubic spline with 4 knots 0.44 3 0.93 
WBC Restricted cubic spline with 4 knots 5.92 3 0.12 
PLT/JOOOO Restricted cubic spline with 4 knots 13.04 3 0.00 
Het Restricted cubic spline with 4 knots 0.94 3 0.82 
Albumin Restricted cubic spline with 4 knots 10.12 3 0.02 
Jog2AST Restricted cubic spline with 4 knots 14.08 3 0.00 
log I Oviraemia Restricted cubic spline with 4 knots 1.03 3 0.79 
Interaction tests 
Age vs. all others 15.32 10 0.12 
Day of illness vs. all others 18.29 10 0.06 
BM I: body mass index; WBC: white blood cell count; PLT: platelet count; AST: aspartate 
am inotransferase 
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Supplementary Table 5-2. Performance of prognostic models for severe dengue amongst laboratory-confirmed dengue 
Full model with predefined candidate predictors Alternative model 
Reduced model by step-wise Reduced model by step-wise (ESDI) 
AIC BIC 
AUC 0.87 0.85 0.83 
Sensitivity 0.81 0.80 0.77 
(95%CI) (0.73, 0.87) (0.72, 0.86) (0.69,0.84) 
Specificity 0.74 0.72 0.71 
(95%CI) (0.72,0.76) (0.70,0.74) (0.69,0.73) 
PPV 0.16 0.15 0.14 
(95%CI) (0.14, 0.20) (0.13, 0.18) (0.12,0.17) 
NPV 0.98 0.98 0.98 
(95%CI) (0.98, 0.99) (0.97, 0.99) (0.97.0.99) 
The starting full model with predefined candidate predictors included all variables listed in Table 5-1. 
Reduced model by step-wise AIC: age. vomiting, white blood cell count, het, platelet count, log2(aspartate aminotransferase). 
NSl rapid test status, loglO(viraemia), serotype. 
Reduced model by step-wise BlC: vomiting, platelet count, log1(aspartate aminotransferase), logI0(viraemia). 
Alternative full model: vomiting, platelet count, log2(aspartate aminotransferase), NS 1 rapid test status. 
AUC: area under the ROC curve, PPV: positive predictive value, NPV: negative predictive value, AIC: Akaike information 
criteria, BIC: Bayesian information criteria, ESDI: Early Severe Dengue Classifier 
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Supplementary Figure 5-1. Plots of estimated component smooth functions of a GAM for the 
risk of severe dengue which included all candidate predictors listed in Supplementary Table 5-1 
and modelled continuous parameters as smooth terms. Only terms estimated to have a non-linear 
association with outcome are displayed. Dots correspond to individual partial residuals; solid lines 
correspond to smooth spline functions estimated by GAM; dashed lines correspond to the 
estimated smooth functions plus/minus one standard error. 
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Statistical appendix 
Assessment of linearity 
A generalized additive model (GAM) with integrated smoothness estimation as 
implemented in the R package mgcv version 1.8-0 was used to assess potential non-linear effects 
of variables on the risk of severe dengue. The model included all candidate predictors listed in 
Table 5-1 and modelled continuous parameters as smooth terms. 
The GAM chose non-linear associations for several parameters including age, BM I, white 
blood cell count, platelet count, Het, AST, albumin and viraemia (Supplementary Figure 5-1). The 
estimated association of outcome with all of these variables was reasonably elose to a linear 
function. Hence, these variables were treated as linear terms. 
Assessment of interactions 
Potential interactions between age, day of illness and haematologieal and biochemical 
results were examined by likelihood ratio tests based on the full model with all variables from 
Table 5-1. 
No interaction between age, day of illness and haematologieal and biochemical results were 
statistically significant (all p-values > 0.05). 
115 
Chapter 6 
GENERAL DISCUSSION AND FUTURE RESEARCH 
The incidence of dengue has grown dramatically around the world in recent decades. 
The actual numbers of dengue cases are underreported and many cases are misclassified. 
Dengue is one of the diseases of most public health concern in Vietnam. The annual 
incidence of dengue per 100,000 persons is tens to hundreds of patients, significantly 
affecting the country's socio-economy. Vietnam is also an endemic country ·where 
four serotypes circulate throughout the year posing a huge disease burden to every 
family in the country. Classic preventive interventions have not brought expected 
outcomes to achieve a reduction in virus transmission. The majority of vector control 
programs such as aerial spraying with insecticides, killing mosquito larva also have 
limited effectiveness. These lead to a high pressure on the hospital sector to follow 
up and provide medical treatment to patients during the outbreaks. The aims of this thesis 
were to document the range of clinical outcomes in children with dengue and to 
develop a simple tool to help physicians not only make early diagnosis of dengue but 
also prediction of severe dengue. 
Although the case mortality rate has reduced significantly in Vietnam 
over the past 20 years, to below 0.1 % for 2014, in many other endemic regions of 
the world the disease has a greater mortality rate. Dengue was ranked 
as the fastest-spreading, vector-borne viral disease in 2012. Dengue cases have 
been reported in several nonendemic countries and territories. Main drivers 
for dengue transmission are urbanization, population growth with poor sanitary 
condition and long distant transportation. The actual numbers of dengue cases are 
underreported because the reports are based on hospitalized dengue patients in 
public hospitals. With the blooming growth of private hospitals and clinics in most 
major cities, it is essential for these healthcare providers to make reports 
to the surveillance system so as we can take intervention measures to prevent the 
outbreak from occurring .. Furthermore, many dengue cases are misclassificd 
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because just a small proportion receive specific diagnostic tests and the final 
classification is taken from the discharge diagnosis, i.e. there will be reported 
dengue cases that are actually not dengue and vice versa. Therefore, a need for active 
surveillance system in the endemic regions must be implemented to document 
the index case on a weekly or even daily basis to help local authorities have 
preparedness and plan for disease control. Health education for community to change 
attitude and behaviours with regard to mosquito as well as larva elimination, 
and above all active surveillance system are the principle measures to tackle epidemic 
dengue. 
The majority of dengue cases reported from the healthcare services are 
based on clinical judgment, using clinical findings and the complete blood counts 
alone. It is important to have a more specific and affordable laboratory 
test as a screening platform in parallel with clinical manifestations and 
complete blood count to achieve a better sensitivity and specificity in dengue 
diagnosis. Such a test is the rapid NS 1 antigen detection assay now available 
with the sensitivity and specificity of approximate 70% and 99% respectively. 
Of note, the NS 1 rapid test status is associated with dengue severity because 
it has close relationship with plasma viral RNA concentration. Although 
the sensitivity of the NS 1 rapid test is not excellent, it is highly specific and does 
not require expertise or complicated facilities compared to RT-PCR and 
serological techniques. It is also difficult to interpret a single anti-dengue JgM 
alone because a positive result can be the persistence of antibodies up to 3 
months after initial infection. Therefore, this may lead to misclassification of 
acute febrile illnesses as dengue due to persistence of anti-dengue JgM occurring 
after dengue infection. On the contrary, a single negative result of anti-dengue 
IgM cannot absolutely exclude dengue infection from an acute febrile patient 
with clinically suspected dengue because anti-dengue JgM antibody generally 
occurs 3-5 days after illness onset and is usually less sensitive in secondary infection. 
Therefore, the NS 1 rapid test should be incorporated to the surveillance system 
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and healthcare facilities at all level should use it routinely in early diagnosis and 
implementation of effective intervention. It is, however, necessary to have more studies 
in evaluating new generation ofNS 1 rapid test to combine NS 1 antigen and antibody results 
to exploit the temporal diagnostic characteristics of each analyte to achieve higher 
performance of the test [192]. 
Our project was the largest prospective cohort study in Vietnam to comprehensively 
investigate clinical and virological characteristics of children with dengue in 
the hottest endemic regions in southern Vietnam. The results from the 
study provide evidence-based insights of dengue and are especially useful in 
terms of 'early diagnosis and prognosis of severe dengue. In endemic countries 
like Vietnam, dengue occurs throughout the year and mainly in the wet 
season. It is impossible to perform hospitalization for every dengue patient in 
a setting with limited resources. It is essential for physicians to recognize 
patients with dengue early and for those at risk of developing severe complications 
to direct appropriate management such as hospitalization or oral fluid intake. 
The effort of WHO to design a new reclassification of dengue disease and 
incorporate this scheme to the Integrated Management Childhood Illness 
algorithm helps health workers assess a sick child's condition, classify the illness, 
treat the child, and counsel the parent. The algorithm consists of case management 
guidelines developed based on evidence from clinical research. The guidelines are 
syndromic meaning they rely on systematic assessment of signs and symptoms with a 
focus on sick children less than 5 years old. Our diagnostic tool has an acceptable sensitivity 
and specificity as well as applicable usage for children from I to 15 years 
of age. Different age setting and region or country-specific validation would be useful to 
increase confidence in the diagnostic algorithm. 
Early prediction of severe dengue is a challenge depending mainly 
on close monitoring every day. The issue is to identify a small proportion of dengue 
cases at risk of developing to severe complications or requiring intravenous fluid 
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infusion to guide attending doctors in the outpatient settings to have appropriate 
management by indication for hospitalization without making more pressure on the 
overload of inpatient wards. The ESDI serves as an adjunct tool to help physicians 
especially general practitioners make clinical judgment about the probability of severe 
dengue of a child with acute onset of fever. The ESDI has a low positive predictive 
value because it predicts a rare outcome; yet it can define a population at high 
risk of severe dengue so that early intervention measures can be taken to reduce 
the actual complications or clinical trials with new medications can be conducted 
on this target group. However, due to a low PPV for severe dengue as commonly 
seen in prediction of a rare outcome, the ESDI can induce overestimation of this 
severe population as well as hospitalization of false positive severe cases. There 
has been robust evidence to establish the association between plasma viral RNA 
concentration and dengue severity. The RT-PCR technique is also highly sensitive 
and specific in making early diagnosis of dengue as well as quantitation of dengue viraemia. 
It is time to consider dengue viraemia by RT-PCR as a necessary laboratory test in endemic 
season where it can help in patient diagnosis, virus surveillance and perhaps in prognosis. 
It is also valuable to use dengue viraemia as an important endpoint in clinical trials in 
therapeutic perspective or preventive measures such as vaccine or the usage of biological 
agent, i.e. Wolbachia, to eliminate dengue. These studies are in progress and have initial 
encouraging results to set up further investigation about the effectiveness of these 
interventions. 
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